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MICRORNAS ASSOCIATED WITH MELANOMA INFLAMMATION
AND RESPONSE TO PD-1 INHIBITION
Robert Szczepaniak Sloane, BSc
Advisory Professor: Jennifer Wargo, M.D., M.M.Sc.
Melanoma is an aggressive malignancy of melanocytes with historically poor
outcomes. Melanoma therapy has improved markedly over the past decade with
advances in molecularly targeted agents and immunotherapies. Immune checkpoint
inhibitors achieve T-cell mediated anti-tumor efficacy by blocking engagement of
inhibitory checkpoints on T-cells to overcome immunosuppressive signals from tumor
cells and the broader microenvironment. Despite these advances, there are a significant
proportion of patients who do not benefit from existing immunotherapy strategies
making it a priority to identify and target the mechanisms that confer resistance to
therapy. We demonstrate that microRNAs are accurate markers of microenvironment
composition with prognostic value for overall survival in melanoma. We also identified
networks of microRNA and mRNA expression in melanoma tissue and melanoma cell
lines that are associated with previously identified melanoma transcriptomic subsets.
These microRNA networks encompass several key oncogenic processes including
epithelial to mesenchymal transition and expression of melanoma specific transcription
factors including MITF. Furthermore, investigation of these microRNAs in a cohort of
PD-1 inhibitor treated melanoma patients identified a survival benefit in patients whose
melanomas had high expression of miR-100-5p and miR-125b-5p. These findings
indicate that microRNA regulation of gene expression in melanoma is relevant to
melanoma biology, composition of the immune microenvironment and outcomes to
PD-1 checkpoint blockade.
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CHAPTER ONE
INTRODUCTION
This chapter is based upon the following work:
-

Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A,
Wargo JA. Interaction of molecular alterations with immune response in
melanoma. Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681.
PMID: 28543700; PMCID: PMC6105277.

TARGETED AND IMMUNE THERAPY FOR MELANOMA
Recent Advances in Clinical Care
Significant advances in the treatment of metastatic melanoma have been made over the last
decade, translating into meaningful survival benefit for patients. Therapeutic strategies
may be broadly characterized into targeted therapy versus immunotherapy approaches—
with several agents now approved by the US Food and Drug Administration (FDA) in each
category. These agents are also being used to treat patients with earlier stage disease;
however, resistance to therapy remains an issue across treatment types.
One of the most frequent mutations in melanoma involves the B‐Raf proto‐oncogene
serine/threonine kinase (BRAF) gene, with BRAF mutations present in approximately 50%
of melanomas, leading to constitutive signaling of the mitogen‐activated protein kinase
(MAPK) pathway in affected cells [1, 2]. Pharmacologic targeting of this oncogenic
mutation has been a qualified success, leading to the approval of several different BRAF
inhibitors (vemurafenib in 2011, dabrafenib in 2013)[3, 4]. However, despite a high
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response rate, the durability of responses has been limited (<6 months), and a deep query
into resistance has ensued, uncovering numerous mechanisms of therapeutic resistance to
BRAF‐inhibitor monotherapy, many of which contribute to MAPK reactivation [5-14]. On
the basis of these findings, investigators developed combinatorial strategies incorporating
mitogen‐activated protein kinase kinase (MEK) inhibition and BRAF‐inhibitor
monotherapy with some success and a near doubling of progression‐free survival [15, 16].
Therapeutic resistance remains an issue even with combined BRAF and MEK inhibition,
and the majority of patients experience relapse of disease within 1 year of initiating therapy
[17-19]. Nonetheless, durable responses may be observed in a subset of patients, and from
20% to 30% of patients remain progression free 4 years into therapy [17].
Concurrent with the clinical development of BRAF‐targeted therapy was the clinical
development

of

immune‐checkpoint

inhibitors.

This

class

of

agents

blocks

immunomodulatory molecules on the surface of T cells (or their ligands), resulting in
reactivation of potentially anergic T cells [20, 21]. Ipilimumab and tremelimumab are
monoclonal antibodies that block the cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) receptor
on the surface of T lymphocytes. CTLA‐4 functions to down‐regulate the priming phase of
an immune response, and blocking this interaction results in T‐cell activation through the
engagement of antigen‐presenting cells. CTLA‐4 blockade may also function through
depletion of immune‐suppressive regulatory T cells by antibody‐dependent cellular
cytotoxicity, increased mobilization of CD8 T cells to the tumor, and prevention of trans‐
endocytosis of costimulatory molecules on antigen‐presenting cells, thereby enhancing
their capacity to prime T‐cell responses [22-24]. Two large phase 3 clinical trials
investigating treatment with ipilimumab in patients with metastatic melanoma
2

demonstrated a survival benefit over then standard‐of‐care chemotherapy, substantiating
its FDA approval in 2011 [25, 26]. Although overall objective response rates are modest
(range, 10%‐15%), treatment with CTLA‐4 blockade is associated with long‐term disease
control in a subset of patients, with approximately 20% of treated patients achieving
durable disease control (>10 years after initiating therapy) [25, 27].
Other immune‐checkpoint inhibitors were also developed during this time, including those
targeting the programmed death‐1 (PD‐1) pathway and its ligands (PD‐L1, PD‐L2). PD‐1
ligation leads to inactivation of T cells, although this mainly affects the effector phase of a
T‐cell response in peripheral tissues (such as in the tumor microenvironment) [28, 29].
Treatment with monoclonal antibodies that block PD‐1 is associated with response rates of
approximately 40% in patients with metastatic melanoma, and 2 such agents were approved
by the FDA in 2014 (pembrolizumab and nivolumab) [30, 31]. It is noteworthy that
treatment with these agents is associated with a lower incidence of toxicity compared with
CTLA‐4 blockade [30, 32-35]. More recently, combination regimens with CTLA‐4 and
PD‐1 blockade were tested in clinical trials and demonstrated a high response rate (>60%)
and improvement in overall survival, although treatment with this regimen is also
associated with a very high rate of toxicity [36, 37].
Additional forms of immunotherapy have been investigated and have demonstrated
efficacy with the FDA approval of talimogene laherparepvec (TVEC) in 2015. TVEC is an
oncolytic herpesvirus that was engineered to express human granulocyte‐monocyte
colony–stimulating factor and is used as an intratumoral injection [38]. TVEC selectively
replicates within tumor cells, causing tumor lysis and is also believed to elicit antitumor
immune responses through enhanced antigen presentation by dendritic cells (DCs) [39-41].
3

This agent was FDA approved for the treatment of unresectable stage IIIB, IIIC, and IV
melanoma based on an improved durable response rate compared with granulocyte‐
monocyte colony–stimulating factor alone [42]. More recently, TVEC was tested in
combination with immune‐checkpoint inhibitors (ipilimumab and pembrolizumab) and
demonstrated greater efficacy than expected with either drug alone; however, these agents
were not compared in a randomized prospective design [43, 44].
Despite these advances, there are still significant proportions of patients who do not
respond to therapy, and therapeutic decision making remains difficult based on different
treatment choices and a paucity of reliable biomarkers for response. However, tremendous
insights into molecular and immune mechanisms of response and resistance to these
therapies have been gained and ultimately may help guide rational approaches to
optimizing treatment.
Insights into the Effects of Mutations on Antitumor Immunity
Over the past decade, we have made significant progress in understanding the effects of
mutations on antitumor immunity. With the advent of next‐generation sequencing and the
use of targeted sequencing panels at the time of melanoma diagnosis, we now have more
information on which to base therapeutic decisions, although the approach to date has been
somewhat rudimentary.
Detailed genomic analyses of large melanoma cohorts have provided understanding of the
key molecular features that contribute to the development of melanoma, including
widespread dysregulation of the MAPK signaling pathway driven predominantly by BRAF
and RAS (neuroblastoma rat sarcoma viral oncogene homolog [NRAS], Harvey rat
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sarcoma viral oncogene homolog [HRAS], Kirsten rat sarcoma viral oncogene homolog
[KRAS]) mutations. Additional significant alterations include phosphatase and tensin
homolog (PTEN) inactivation either by mutation or deletion, and neurofibromatosis type
1 (NF‐1) mutations [45, 46]. It is also known that cutaneous melanoma has the highest
mutational burden among all cancers, likely related to damage by ultraviolet (UV) radiation
[47]. Over the last decade, it has become apparent that the different molecular alterations
can have distinct effects on the tumor microenvironment, which, in turn, influence the
response to targeted therapies and immunotherapies [48, 49]. Thus, a deeper understanding
of the immune effects of genomic mutations (and consequences of targeting these
mutations) may facilitate the design of effective treatment strategies. Specific aspects of
selected mutations and/or genomic alterations are discussed below. It is worth noting that
several additional mutations may influence immune responses, but here we are highlighting
the high‐frequency mutations with strong evidence for an impact on antitumor immunity.
BRAF Valine‐to‐Glutamic Acid Mutations at Codon 600
Activating mutations in the BRAF gene (most commonly the valine‐to‐glutamic acid
mutation at codon 600 [V600E]), lead to 10‐fold greater kinase activity than that observed
in normal cells, resulting in aberrant MAPK pathway activation, which protects
melanocytes from apoptosis while driving tumorigenesis, invasiveness, and metastatic
behavior [50]. It is noteworthy that this mutation also reportedly plays a role in immune
evasion [51-53]. The first mechanistic report of the immunosuppressive effects of BRAF
in melanoma came from Sumimoto et al in 2006 [51]. In their study, interleukin 6 (IL‐6),
IL‐10, and vascular endothelial growth factor (VEGF) were identified and validated as
immunosuppressive factors from the supernatant of cultured BRAFV600E melanoma cells,
5

and these factors and their immunosuppressive function were reduced with pharmacologic
MEK inhibition or BRAFV600E RNA interference treatment [48, 51]. At the same time,
Kono et al demonstrated that BRAFV600E can suppress the expression of the melanoma
antigens melanoma antigen recognized by T cells 1 (MART‐1) and glycoprotein 100
(gp100), whereas MEK inhibition reverses this effect, also leading to increased recognition
and killing by MART‐1–specific cytotoxic T cells [52]. Khalili and colleagues also
observed that BRAFV600E mutations caused immunosuppression by inducing IL‐1
transcription in both melanocytes and melanoma cell lines, resulting in enhanced ability of
melanoma tumor‐associated fibroblasts to suppress cytotoxic T‐cell activity [54].
These in vitro findings are supported by preclinical models and translational work in human
melanomas by several groups [48, 49, 53-58]. Notably, longitudinal tissue immune
profiling of patients undergoing selective BRAF inhibition with or without MEK inhibition
demonstrated an increase in CD8‐positive T‐cell infiltrate within 2 weeks of initiation of
treatment, an increase in the expression of melanoma antigens on tumor cells, an increase
in markers of T‐cell cytotoxicity, and a decrease in levels of immunosuppressive cytokines
IL‐6 and IL‐8 (Figure 1.1) [49, 59]. It is noteworthy that immunomodulatory molecules
PD‐1 and PD‐L1 were also increased with treatment. This is likely a mechanism of adaptive
immune resistance, induced by tumor‐infiltrating lymphocyte (TIL)‐derived interferon
gamma (IFN‐γ). However, it is important to note that, although PD‐1/PD‐L1 interaction is
inhibitory, induction of these molecules as a result of BRAF therapy provides additional
therapeutic targets in light of FDA approval of anti‐PD‐1 and anti‐PD‐L1 therapies,
strengthening the rationale for combining targeted therapies with immune‐checkpoint
blockade.
6

Figure 1.1 Immune Effects of Molecular Alterations in Melanoma
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Figure 1.1 Immune Effects of Molecular Alterations in Melanoma
Immune effects of molecular alterations within the tumor microenvironment are illustrated.
Immune effects of the B‐Raf proto‐oncogene serine/threonine kinase (BRAF) valine‐to‐
glutamic acid mutation at codon (BRAFV600E) and phosphatase and tensin homolog
(PTEN), β‐catenin, and passenger mutations resulting in neoantigens on the immune tumor
microenvironment are described. It has been established that the BRAFV600E mutation
up‐regulates the immunosuppressive cytokines vascular endothelial growth factor (VEGF),
interleukin 1 (IL‐1), IL‐6, and IL‐10 and down‐regulates immunogenic melanoma
antigens. It also has been demonstrated that PTEN loss increases the expression of VEGF,
IL‐6, IL‐10, and C‐C motif chemokine ligand 2 (CCL2), leading to reduced T‐cell
infiltration and poor response to checkpoint blockade. Aberrant β‐catenin activity leads to
increased expression of IL‐10, reducing the ability of dendritic cells to mediate an
antitumor T‐cell response. Increases in mutational load and neoantigens result in a potential
increase in the antigenicity of the tumor. MHC I indicates major histocompatibility
complex class 1.
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Despite evidence for the immunosuppressive role of BRAF in vitro and in translational
studies, meta‐analyses of immunotherapy trials have not demonstrated a significant
difference in response rates for patients with versus without a BRAF mutation [60]. This
could have been because of insufficient power to detect a difference, or it may be related
to the presence of other molecular and microenvironment factors affecting antitumor
immunity. Nonetheless, it suggests that BRAF mutation status as a single variable is not
sufficient to predict response to immunotherapy.
PTEN
Expression of the tumor suppressor PTEN is lost in up to 30% of melanomas, and loss of
PTEN function is associated with aberrant activation of the phosphoinositide 3‐kinase
(PI3K) pathway, which can cooperate with mutant BRAF during tumorigenesis [61, 62].
In melanoma, PTEN loss is associated with both reduced T‐cell infiltration and reduced T‐
cell function in vitro and in vivo, and 2 separate studies have outlined the mechanisms of
immune suppression that occur with PTEN loss [45, 63]. Like in BRAF‐mutant melanoma,
IL‐6, IL‐10, and VEGF expression levels are key immunosuppressive features of PTEN
inactivation, with PI3K signaling through signal transducer and activator of transcription
3 (STAT3) mediating the expression of these cytokines [63]. Furthermore, the
immunosuppressant C‐C motif chemokine ligand 2 (CCL2) is also overexpressed in
PTEN‐inactivated tumors [45]. It is encouraging to know that the effects of PTEN loss on
both cytokine expression and T‐cell infiltration and function are reversible with PI3K
inhibitors, which increased the efficacy of anti–PD‐1 therapy when administered in
combination in a murine model [45]. These studies also demonstrated that PTEN loss is
associated with reduced T‐cell infiltration, reduced efficacy of ex vivo expansion of TILs,
9

and poor response to anti‐PD‐1 checkpoint blockade in human studies (Figure 1.1)[63].
This concept is now being translated to the clinic, and a trial is underway to test the safety
and efficacy of combining a PI3K inhibitor with pembrolizumab in melanoma and other
tumor types (clinicaltrials.gov identifier NCT02646748). One of the stated aims of this
study is to investigate effects on the tumor microenvironment, which may help clarify the
immune‐related role of PI3K and the clinical feasibility of this combination. Notably,
potential nuances exist with this type of approach, because studies have indicated that
different isoforms of PI3K inhibitors have differential effects on T lymphocytes [64].
NRAS
NRAS mutations are present in approximately 20% of melanomas, representing the second
largest molecular subtype after BRAF‐mutant melanoma [65, 66]. Activating mutations in
NRAS, like BRAF, result in constitutive over‐activation of the MAPK pathway [67, 68].
However, NRAS‐mutant melanomas are also clinically distinct from BRAF‐mutant
melanomas, with a higher incidence in chronically sun‐damaged skin, thicker lesions at
presentation, and poorer prognosis [69].
The clinical response to immunotherapy is also different in the presence or absence of an
NRAS mutation. Two independent studies have now observed a higher response rate to
immunotherapy in NRAS‐mutated melanomas. In an analysis of 208 patients with stage
III/IV melanomas who received treatment with high‐dose IL‐2 (HD‐IL‐2), those who had
NRAS mutations achieved significantly higher response rates compared with those who
had BRAF‐mutant or wild‐type (WT) melanomas [70]. These findings were recently
corroborated in a study that included HD‐IL‐2, ipilimumab, and anti–PD‐L1/PD‐1
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therapies. Although increased response rates were observed in all immunotherapies, the
benefits were most pronounced with the anti–PD‐L1/PD‐1 treatments [71].
The mechanism of these improved responses has not yet been fully elucidated. Joseph et
al reported a correlation between serum lactate dehydrogenase (LDH) levels and response
to HD‐IL‐2, although LDH is a surrogate of disease burden and a prognostic biomarker in
melanoma and this may be the basis of the association, rather than a specific association
with an immune phenotype [70, 72]. Elevated expression of PD‐L1 in the NRAS cohort
described by Johnson et al could explain these clinical differences, although their
observations were in a small cohort and were not statistically significant [71]. The
differential response to immunotherapies may also be explained in part by the specific
immunosuppressive effects of BRAF mutation and PTEN loss in the other cohorts,
especially because NRAS mutations are generally exclusive of both BRAF mutation and
PTEN loss, which would clearly delineate these cohorts [69].
Wnt/β‐Catenin Signaling Pathway
Although mutations in the Wnt/β‐catenin pathway occur at a relatively low rate in
melanoma, it has been reported that dysregulation of this pathway is common, with 1 report
of abnormal cytoplasmic/nuclear accumulation in one‐third of melanomas [73, 74]. It is
noteworthy that defects in the Wnt/β‐catenin signaling pathway have been implicated in
immunosuppression as an intrinsic mechanism within melanomas and also within local
DCs [75-77]. Activation of β‐catenin signaling directly increases expression of the
immunosuppressive cytokine IL‐10 in human melanoma, and this is linked to a reduced
ability of DCs to stimulate a melanoma‐specific, CD8‐positive T‐cell response [78]. Two
studies have demonstrated that DC‐mediated inhibition of CD8‐positive T‐cell cross‐
11

priming itself is a process regulated by the Wnt/β‐catenin pathway within the DCs [76, 79].
In addition, tumor‐induced β‐catenin activity in DCs can also induce regulatory T‐cell
differentiation [77]. Recent evidence also suggests that Wnt/β‐catenin signaling in
melanoma cells is linked to T‐cell exclusion from the tumor microenvironment and that
this is mediated by CCL4 transcription and a reduction in the recruitment of CD103‐
positive DCs [75].
When considering the potential clinical relevance of these findings, it is interesting to note
that Wnt/β‐catenin signaling‐linked immunosuppressive effects can be reversed by
pharmacologic targeting of the pathway [77, 79]. It may also be of therapeutic benefit that
Wnt/β‐catenin signaling can regulate immunosuppressive processes in different cell types
through various mechanisms. Therefore, any targeting of this pathway may be broadly
immunosensitizing, and this may improve efficacy and limit potential mechanisms of
resistance (Figure 1.1).
Mutational Load/Neoantigens
Cutaneous melanoma is the most heavily mutated of all cancers because of induction of C‐
T transitions at dipyrimidine sites through exposure to UV irradiation [47, 65, 80].
Accumulation of these mutations often leads to alterations in the MAPK pathway in
melanoma and in other melanoma driver genes, although UV exposure also leads to the
generation of large numbers of other mutations that affect genes unrelated to proliferation
or apoptosis and thus are unlikely to directly contribute to cancer progression [65].
However, recent work has brought to light the role that these “passenger mutations” may
play in altering tumor immunogenicity [80].
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Although high mutational load was once considered to be deleterious in cancer, it is now
thought to have potentially beneficial immunogenic properties [80, 81]. The reasoning
behind this is that a higher mutational load is generally associated with a higher level of
neoantigens, which are defined as tumor‐restricted antigens derived from mutations within
transformed cells [82]. Considering the origin and randomness of their generation,
neoantigens may be associated with increased tumor immunogenicity, because they are
excluded from self‐tolerance and deletion mechanisms at play during T‐cell development.
Increased mutational load and neoantigen burden therefore potentially allow for increased
tumor immunogenicity through presentation of unique peptides more likely to be
recognized by T cells (Figure 1.1).
Accordingly, neoantigen burden has been studied in the context of treatment with immune‐
checkpoint blockade as well as other forms of immunotherapy, such as adoptive T‐cell
therapy [80, 81, 83]. In the setting of treatment with CTLA‐4 and PD‐1 blockade, a higher
mutational burden is correlated with favorable responses [80, 81, 84]. However, this is not
specific to melanomas and has been observed in other cancer types, including non‐small
cell lung cancer as well as colorectal cancer, with high mismatch‐repair mutations [85].
Although original reports relied on whole‐exome sequencing to derive mutational load,
algorithms have now been developed to calculate the “predicted total mutational load”
from targeted sequencing panels of 200 genes [86]. In addition to these quantitative
assessments, qualitative assessments of neoantigens have been used to develop
personalized cancer therapies through the identification of neoantigens in tumors and
validation of expression and reactivity against these antigens by autologous T cells [83].
Targeting of patient‐restricted neoantigens has proven successful in this context, as
13

demonstrated in a study by Tran and colleagues in which exome sequencing was
performed, neoantigens were predicted based on patient human leukocyte antigen alleles,
and infusion of mutated Erbb2 interacting protein (ERBB2IP)‐specific T cells mediated the
response of multiple metastases in a patient with epithelial cancer [80, 83].
Molecular Alterations with Response/Resistance to Immunotherapy
In addition to interrogating known melanoma mutations for their influence on antitumor
immunity, tremendous progress has been made in identifying resistance‐conferring
molecular alterations through the analysis of patient cohorts that received immunotherapy.
Several high‐impact studies have been done over the last several years, and the insights
gained are informing strategies to overcome therapeutic resistance.
In addition to the influence of mutational load, as described above, several other factors
have been associated with response or resistance to immune‐checkpoint blockade [80].
Genomic and transcriptomic characterization of a cohort treated with CTLA‐4 blockade
revealed that neoantigen burden and the expression of cytolytic markers also are associated
with long‐term clinical benefit [84]. Additional studies in the setting of CTLA‐4 blockade
have identified other mutations associated with improved survival, such as serpin peptidase
inhibitor, clade B, member 3 (SERPINB3) and SERPINB4 mutations, which are
hypothesized to enhance tumor immunogenicity [87]. Defects in IFN signaling may also
serve as a mechanism of resistance to therapy, and studies have demonstrated that
functional IFN‐γ is necessary for a successful immune response to CTLA‐4 therapy [88,
89].
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Several recent reports have also described molecular alterations associated with response
and resistance to PD‐1 blockade. Like CTLA‐4 blockade, high mutational load is also
associated with long‐term clinical benefit [90, 91]. In addition, it has been demonstrated
that responding tumors have a higher burden of mutations in breast cancer 2 (BRCA2), a
DNA repair gene [90]. Therapeutic resistance is associated with defects in the antigen
processing and presentation machinery (such as β2‐microglobulin) and IFN‐γ signaling as
well as up‐regulation of genes involved in angiogenesis, extracellular matrix remodeling,
cell adhesion, and mesenchymal transition [89, 90]. In addition, a recent study
incorporating targeted sequencing revealed that patients with NF‐1 mutations had high
mutational load and high response rates to anti‐PD‐1, whereas patients who lacked
BRAF/NRAS/NF‐1 mutations had low mutational load [91]. One study to date has been
published analyzing sequential treatment with CTLA‐4 and PD‐1 blockade that performed
immune and gene‐expression profiling in longitudinal tumor samples in the context of
therapy [92]. In those studies, immune signatures in pretreatment samples were only
modestly predictive of response to both CTLA‐4 blockade as well as PD‐1 blockade;
however, the presence of a favorable immune signature in on‐treatment tumor biopsies was
highly predictive of response, particularly to anti–PD‐1 therapy. More recently, genomic
characterization of tumor samples has been performed in the same cohort, demonstrating
copy number alterations as drivers of resistance to both forms of immune‐checkpoint
blockade [93].
Combining Targeted Therapy and Immunotherapy
With an understanding of the immune effects of oncogenic mutations and consequences of
their therapeutic targeting, coupled with a growing appreciation of molecular resistance
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mechanisms to immunotherapy—one may question if synergy will be seen when these
agents are combined. Indeed this hypothesis has been posed, though early interest in
combining targeted therapy and immunotherapy was largely clinically based—hoping to
achieve high response rates (characterized by targeted therapy) and durable responses
(characterized by immunotherapy). Since these trials were initiated, there is now also
growing scientific rationale for combining these 2 treatment modalities, and a large number
of trials exploring this strategy are currently underway [94-97].
One of the first phase 1 clinical trials testing a BRAF inhibitor with immunotherapy
involved the combination of BRAF inhibitor monotherapy (with vemurafenib) and a
checkpoint inhibitor (targeting CTLA‐4, ipilimumab). Although responses were observed
and there was evidence of synergy based on assessment of T‐cell infiltrates within tumors
from these patients, accrual to the trial was halted early, because grade 3 hepatotoxicity
was observed in a significant proportion of these patients (6 of 12), highlighting the
potential toxicity of these combinations [94, 98].
Another trial focused on the combination of BRAF and MEK inhibitors (dabrafenib and
trametinib) with immune‐checkpoint blockade targeting CTLA‐4

(ipilimumab;

clinicaltrials.gov identifier NCT107767454) in patients with stage IV, BRAF‐mutant
melanoma. In that trial, hepatotoxicity was still observed, although the magnitude was far
less, suggesting that this may be drug specific rather than target specific [96]. Notably, the
arm of the trial that incorporated treatment with the triplet combination was closed after
several patients (2 of 7) developed colitis, with 1 patient requiring surgery [99]. This again
highlights the unpredictability of toxicity profiles and the need for carefully designed and
monitored, early phase clinical trials.
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Compared with concurrent therapy, a phase 2 trial of sequential vemurafenib and
ipilimumab demonstrated a more tolerable and manageable toxicity profile—65% of
patients had grade ≥3 toxicities, the majority of which were skin toxicities—suggesting
that combining these drugs in this manner may prove more beneficial [97]. Finally, given
the improved tolerability of anti–PD‐1/PD‐L1 axis‐targeting therapies compared with
ipilimumab, trials are investigating combinations of these agents with targeted therapies.
A recent report on a phase 1 trial of durvalumab/dabrafenib/trametinib for BRAF‐mutant
melanoma,

durvalumab/trametinib

for

BRAF‐WT

melanoma,

and

sequential

trametinib/durvalumab in BRAF‐WT melanoma has also demonstrated a relatively more
manageable toxicity profile, suggesting that combination with anti–PD‐1/PDL‐1 agents
may be preferable [100].
In recent years the combination of a BRAF and MEK inhibitor (Vemurafenib and
Cobimetinib) with an anti-PDL-1 agent (Atezolizumab) has been investigated in a multicenter, randomized, double blind, placebo-controlled phase III trial (NCT02908672). This
trial reported increased progression free survival of melanoma patients treated with the
triple combination compared to those treated with Vemurafenib and Cobimetinib and a
placebo (15.1 months vs 10.6 months) [101]. There was no significant difference in
objective response rates between the different arms of this trial and the largest differences
in PFS were observed after 6 months. The results of this trial lead to the FDA approval of
this combination in July 2020 for melanoma patients with BRAFV600E mutated,
unresectable or metastatic melanoma.
Additional trials are underway exploring combinations of immunotherapy and targeted
therapy. However, as results emerge, it is becoming increasingly clear that complexities
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exist with this approach; therefore, efforts must be made to use scientific evidence and
iterative input from ongoing and completed trials to guide next‐generation combination
studies.
Refining Combination Strategies through Biomarker-Driven Clinical Trials
Insights from preclinical models and translational research are paramount as we charter a
path forward with rational combination strategies. This is important, because the numbers
of patients required to test all possible combinations of molecular‐targeted and immune‐
targeted therapies using conventional clinical trial designs far exceed the numbers of
available patients for such studies. Thus it may be necessary to move to more novel,
biomarker‐heavy clinical trial designs in an effort to incorporate insights gained from
genomic and immune analyses (Figure 1.2).
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Figure 1.2 Adaptive Trial Design to Utilize Personalized Medicine

Figure 1.2. Adaptive clinical trial design allows improved therapeutic decisions. (A)
Current approaches investigate limited molecular biomarkers before initiation of a standard
therapy in a heterogeneous patient population with little personalization. This results in
modest and variable responses. (B) Increasing numbers of trials now allow for adaptive
decision making. These trials include more extensive molecular and immune profiling
before a personalized medicine approach. Then, after treatment initiation, an early on‐
treatment biopsy is obtained for molecular and immune profiling to evaluate the success of
the current therapy. Because of this profiling, patients are either continued on this therapy
or switched to an alternate treatment regimen, enhancing responses to therapy.
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From a trial standpoint, adaptive trial design provides 1 possible means of more efficiently
assessing combination therapies [102]. In this design, Bayesian modeling may be used to
combine a priori hypotheses and estimation of variables along with data collected from the
ongoing trial regarding efficacy and toxicity. On the basis of an adjusted set of parameters
at prespecified interim analyses, the trial design can be modified regarding dose escalation,
sample size, population or subpopulations studied, treatment allocation, randomization
probabilities, and study endpoint (for example, changing from superiority to noninferiority
endpoint), among other variables [102]. An example in melanoma in which an adaptive
trial design was used is the LOGIC 2 trial, which was designed to combine initial treatment
with BRAF and MEK inhibitors, binimetinib and encorafenib, until the time of progression,
at which point patients received 1 of several different treatments based on the molecular
profile of their biopsy at the time of progression. The trial also incorporated Bayesian
modeling based on accumulating toxicity data to minimize the number of patients on doses
with excessive toxicity and maximized exposure to doses that were both tolerable and
efficacious. Such a flexible design approach allows for more efficient testing of
combinations that can ascertain efficacy, minimize toxicity, and use data from biomarker
analysis.
Furthermore, it is prudent to take findings gained from translational research studies back
to appropriate preclinical models, with validation and optimization of different
combination strategies, before returning these insights to patients (Figure 1.3). An example
of this type of an approach was recently published, describing the immunosuppressive
effects of PTEN loss and responses to immunotherapy [45]. In those studies, tumor samples
from patients with melanoma were interrogated and noted to have exclusion of CD8‐
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Figure 1.3 Translational Research to Improve Melanoma Treatment

Figure 1.3. Translational studies provide an optimal approach to understanding
mechanisms and accelerating patient benefit. Much success has come from approaches
investigating longitudinal patient samples from clinical trials. These samples are then used
to formulate hypotheses and develop appropriate animal models in which therapeutic
mechanisms of response and resistance can be investigated and better understood to
improve patient outcomes.
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positive T cells in regions of PTEN loss within tumors. The impact of this on response to
anti–PD‐1 therapy was assessed, and an association was demonstrated between PTEN loss
in tumors from patients with lack of response to PD‐1–based therapy [45]. These findings
were then translated to a murine model and indicated that treatment of mice with combined
PI3K pathway inhibitors and PD‐1 checkpoint blockade was associated with delayed tumor
outgrowth and enhanced survival. This research is now being translated again back to
patients in the form of clinical trials combining PI3K inhibitors with immune‐checkpoint
inhibitors (clinicaltrials.gov identifier NCT02646748).
Challenges
Despite the successes and insights gained from these studies, major obstacles inherently
remain. First, although several molecular features, such as total mutational load, the burden
of copy number losses, and others described in this review, are associated with responses
to immunotherapy, there is significant overlap between responders and non-responders
with regard to each of these variables; therefore, each on its own is not a reliable biomarker.
Recent studies suggest that an integrated analysis of several of these variables may prove
more useful in predicting responses, although this needs to be validated in larger cohorts
and across cancer types [93].
In addition, recent studies suggest that early on‐treatment biopsies may be far superior to
baseline biopsies in predicting therapeutic response; however, tumors are not always
readily accessible for sampling, and limitations in the amount of tissue obtained with
biopsies may limit the analyses that may be performed [45, 103]. In addition, despite their
better predictive ability, these on‐treatment signatures require treatment of patients with 1
or 2 cycles of their therapies, which is not ideal in the long term and highlights the need to
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identify pretreatment biomarkers of response to therapy. Although it is currently limited,
the identification of biomarkers within liquid biopsies may hold the most promise in the
least invasive manner and make on‐treatment biopsies more pragmatic. “Liquid‐biopsy”
approaches are in development for melanoma and other cancers. Another promising
approach is using a quantitative methods to analyze positron emission tomography (PET)
and computerized tomography (CT) scans to identify previously unappreciated metrics
from diagnostic and staging images that may have prognostic or predictive value. These
techniques are non-invasive and already routinely used clinically [104]. Another related
technique is using deep learning tools to assess histopathological images, again to identify
previously unappreciated features within routinely used diagnostic images that may have
utility as biomarkers [105]; however, large studies will be needed to validate their
prognostic and predictive role [106, 107].
MicroRNAs as Potential Biomarker and Therapeutic Options in Melanoma
Targeted therapy and immunotherapy, as described above, represent major advances in the
treatment of melanoma, offering a real and tangible opportunity to help achieve long‐term
disease control and cures. However, resistance mechanisms to these therapies, either alone
or in combination, continue to emerge. A more comprehensive understanding of molecular
alterations in melanoma and of the molecular mechanisms that contribute to immune
evasion will allow us to design better and more effective treatment strategies in this age of
personalized cancer therapy. One area of research that offers insight into molecular
mechanisms of melanoma biology and immune evasion, as well as a potential source of
prognostic and predictive biomarkers are the posttranscriptional regulators of gene
expression, microRNAs.
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Canonical MicroRNA Biogenesis in Humans
MicroRNA genes are transcribed by RNA Polymerase II, generating the primary
microRNA transcript (pri-miRNA)[108]. The principal feature of the pri-miRNA is a ~80
nucleotide hairpin structure containing what will become the functional, mature microRNA
[109, 110]. The pri-miRNA is processed in the nucleus by a ‘microprocessor complex’
comprised of the RNAIII-family nuclease Drosha and the double stranded RNA binding
protein DGCR8 [111, 112]. The microprocessor complex excises the hairpin from the
RNA strand to form a precursor microRNA (pre-miRNA), which is then transported to the
cytoplasm by the nuclear export protein Exportin 5 [113]. Once in the cytoplasm, the premiRNA is further processed into a 22 nucleotide long, double stranded microRNA duplex.
This is achieved by excising the loop of the pre-miRNA hairpin, a process mediated by
another RNAIII-family nuclease, Dicer [114, 115]. The microRNA duplex contains two
potential mature microRNAs and are named according to which end of the pre-miRNA
hairpin they are from, either 3’ or 5’, thus each microRNA gene can potentially generate
two mature microRNAs [116]. The second role of Dicer is to transfer one strand of the
microRNA duplex to an Argonaute(AGO) protein to form the functional microRNA
induced silencing complex (miRISC). Dicer and the microRNA duplex associate with a
trans-activation-responsive-RNA-binding-protein (TRBP) and the AGO protein to form
the miRISC loading complex [117]. One strand of the microRNA duplex is then
preferentially loaded onto the AGO protein to create the miRISC - a functional complex
capable of interacting and regulating mRNA sequences complementary to the loaded
microRNA [118]. Preferential loading of the 3’ or 5’ microRNA is normally determined
by the strength of nucleotide interactions at the 5’ end of each strand in the microRNA
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duplex, typically leading to one microRNA strand being overrepresented in the final
miRISC [116]. However, post-transcriptional modifications of pre-miRNA can disrupt this
equilibrium and skew expression of 3’ or 5’ microRNAs [116, 119]. The mature RISC
complex resides primarily on rough endoplasmic reticulum, where mRNA:miRISC
interactions can be concentrated [120].
MicroRNA Induced Silencing Complex Specificity and Function
The mature miRISC complex presents two regions of the microRNA molecule on the
external surface of the miRISC complex that bind complementary sequences located on
available mRNA molecules [121]. The two regions of the microRNA that are available to
bind are nucleotides 2-8, known as the seed region, and nucleotides 13 to 16, known as the
supplementary region; the complementary sequence in the mRNA molecule is located in
the 3’ UTR and is called the microRNA Response Element (MRE) [121]. The primary and
highest affinity determinant of the miRISC-mRNA binding is 100% sequence
complementarity between the seed sequence and the MRE as well as an Adenine in the
MRE corresponding to microRNA nucleotide [122, 123]. Functional binding can still
occur without the corresponding Adenine or with a mismatch between nucleotide 8
although this is of lower affinity [122, 123]. A miRISC-mRNA complex prevents
translation and can lead to degradation of the bound mRNA, thus the miRISC complex can
repress gene expression with high specificity and precision. Two additional features of
miRISC-mRNA interactions provide layered regulation of gene expression; microRNA
multiplicity and cooperation. MicroRNA multiplicity refers to the number of MREs present
in the transcriptome. Each microRNA will normally have complementary MRE in dozens
of genes and each mRNA allowing a single microRNA to regulate multiple genes.
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MicroRNA cooperation refers to the number of MREs for more than one microRNA in a
single mRNA. This allows more than one microRNA to cooperatively regulate shared
mRNA targets. Together, variations in the abundance of each microRNA, abundance of
MREs specific to each microRNA and competition between multiple microRNAs for
MREs on the same mRNA leads to a highly complex but organised regulatory system
where cell-type specific microRNA stoichiometry can lead to distinct phenotypes [124].
MicroRNAs in Melanoma
MicroRNAs have an established role as tumor suppressors and oncogenes across multiple
cancer types, with extensive mechanistic evidence related to the hallmarks of cancer [124,
125]. MicroRNA expression has been extensively characterized in melanoma tissue, the
most comprehensive example of this is the microRNA sequencing within the melanoma
TCGA dataset [126, 127]. In this study three distinct transcriptomic subsets of melanoma
were identified that were independent of their mutation status. These subsets were
classified as ‘Keratin’, ‘MITF-low’ and ‘Immune’ based on their unique transcriptomic
features. Of note, a distinct group of microRNAs were associated with each transcriptomic
profile providing evidence for a unique post-transcriptional regulatory microRNA network
associated with different molecular subtypes of melanoma. Clinical and preclinical studies
of individual microRNAs have yielded extensive evidence for their roles in multiple
oncogenic processes in melanoma including sustained proliferative signaling, resisting cell
death, invasion and metastasis, tumor-promoting inflammation and avoiding immune
destruction (Figure 1.4)[128].
MicroRNAs in Immuno-Oncology
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In addition to their proven role as oncogenes and tumor suppressors, there is emerging
evidence for the role of microRNAs in tumor immune evasion [129-134]. Several notable
examples exist from different cancer types that illustrate the potential for microRNA
regulation of immunological molecules and pathways that may have clinical applications
in support of immune checkpoint blockade. The first of these examples is the identification
of the role of miR-200 in epithelial to mesenchymal transition and metastasis in non-small
lung cancer [134]. In this study, Chen et, al demonstrated that miR-200 could
simultaneously suppress metastasis and PD-L1 expression and when miR-200 was itself
repressed by the pro-metastatic ZEB1, there was increased metastasis, and
immunosuppression through expression of PD-L1 [134]. In Glioma, miR-124, was
identified as a repressor of STAT3 signaling, which normally allows glioma cells to
generate an immunosuppressive microenvironment through T-cell suppression and Tregulatory cell induction [135]. By expressing miR-124 in Glioma cancer stem cells,
STAT3 signaling was diminished and markers of immunosuppression in the tumor
microenvironment were reversed [135]. Separately, miR-138 was identified as a regulator
of both CTLA-4 and PD-1 checkpoint molecules and subsequent expression of miR-138
in murine CD4 T-cells improved the immune-clearance of glioma in vivo [136]. Also in Tcells, miR-155 has been shown to have an important role in cytotoxic activity and in-vivo
models lacking miR-155 expression have defective T-cell activity and impaired anti-tumor
efficacy [130, 131].
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Figure 1.4 MicroRNAs Associated with Hallmarks of Cancer in Melanoma

Figure 1.4 MicroRNAs in Melanoma: Extensive evidence for the role of microRNAs in
melanoma biology exists. Presented is a summary of microRNAs with published evidence
for regulatory roles of the hallmarks of cancer in melanoma [128].
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In melanoma, there is pre-clinical evidence for the role of miR-146a in immune-evasion
[137]. In this study, Mastroianni et.al identified miR-146a as overexpressed in melanoma
and a subsequent miR-146a-/- knockout mouse model was shown to improve immune
control of melanoma tumors, indicating that miR-146a is a negative regulator of immune
activation [137].
Dissertation Overview
Immunotherapy has dramatically improved the outcome for many melanoma patients,
however, approximately half of patients do not receive durable responses. The mechanisms
of resistance to immunotherapy are only partly understood and effective therapies to
overcome them are urgently required.
MicroRNAs are major post-transcriptional regulators of gene expression and the aberrant
expression and activity of microRNAs is involved in multiple oncogenic processes. In
melanoma, these processes include proliferation, resisting cell death and activation of
invasion and metastasis. There is also evidence that microRNAs can also regulate the tumor
microenvironment and response to immunotherapy. To date, this has not been extensively
studied in humans and could reveal important mechanisms of immune evasion that could
be targeted therapeutically.
The central hypothesis that we tested is: Micro-RNAs are contributing to the differential
responses of melanomas to checkpoint blockade through post-transcriptional
regulation of immunomodulatory molecules and pathways.
We tested the central hypothesis by investigating the following specific aims:

29

Aim 1: Identify microRNAs associated with immune infiltration and exclusion in
TCGA Melanomas and elucidate mechanisms of immune regulation. RNA and
microRNA sequencing data from TCGA melanoma tissue samples were used to
characterize the immune landscape of melanoma and identify microRNAs that were
enriched or depleted in samples with specific immune features. Using databases of known
microRNA targets we were able to identify immune-associated microRNAs, miR-155-5p,
miR-508-3p and miR-509-3p that had known roles in immune signaling pathway
regulation, cytokine secretion and expression of other immune-regulatory molecules.
Additionally, we validated these targets in vitro, demonstrating their role in modulating
cytokine secretion, MHC expression and sensitivity to T-cell killing. The results from this
aim are shown in Chapter 2.
Aim2: Characterize the mRNA and microRNA profiles associated with response to
PD-1 immunotherapy in melanoma. RNA and microRNA-sequencing data from pretreatment melanoma biopsies from PD-1 treated patients was used to identify similar
groups of tumors based on their gene expression using an unsupervised clustering
approach: Clusters identified by this approach largely overlapped with clinical and immune
parameters, including RECIST response. Differential expression analysis and pathway
analysis identified known and novel enriched genes and pathways associated with PD-1
inhibitor response. We then identified miR-31-5p, miR-200b-3p and miR-205-5p were
associated with response to PD-1 therapy and validated their role in melanoma sensitivity
to T-cell killing in vitro. The results of this aim are shown in Chapter 3.
Aim3: Construct Melanoma Tissue and Cellular MicroRNA-mRNA Networks to
Identify Melanoma Intrinsic MicroRNA-mRNA Networks and Test Their
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Association with PD-1 Inhibitor Outcomes. We constructed microRNA-mRNA
networks using two large databases of melanoma tissue and melanoma cell lines with
microRNA and mRNA sequencing data available. We identified shared as well as tissue
specific networks comprising known ‘Immune’, ‘Keratin’ and ‘MITF-low’ transcriptomic
profile associated microRNAs. We identified known and novel gene set enrichment
associated with each network, indicating distinct phenotypic associations. Using Cox’s
proportional hazard model we were able to demonstrate that the microRNAs, miR-100-5p
and miR-125b-5p, identified as central to the ‘MITF-low’ network, were positively
associated with overall survival in PD-1 inhibitor treated melanoma patients.
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CHAPTER TWO
MICRORNAs ARE ASSOCIATED WITH AND CAN REGULATE IMMUNE
FEATURES IN MELANOMA
INTRODUCTION
Melanoma and Resistance to Immunotherapy
Melanoma is an aggressive malignancy of melanocytes with a 5-year survival rate of 20%
for metastatic disease. Melanoma diagnoses are predicted to reach 91,270 and to cause
9,320 deaths in the US in 2018 [138]. Melanoma therapy has improved markedly over the
past decade with advances in molecularly targeted agents and immunotherapies. Immune
checkpoint inhibitors achieve T-cell mediated anti-tumor efficacy by blocking engagement
of inhibitory checkpoints on T-cells to overcome immunosuppressive signals from tumor
cells and the broader microenvironment [21, 139]. Monoclonal antibodies that target the
immune checkpoint molecules cytotoxic T-lymphocyte antigen 4 (CTLA-4) and
programmed death-1 (PD-1) have achieved a response rate of 61% and 3 year overall
survival of 58% in combination [37, 140]. Despite these advances, there are a significant
proportion of patients who do not benefit from existing immunotherapy strategies. While
some melanoma intrinsic mechanisms of resistance have been identified, such as impaired
antigen presentation and defects in IFN-γ signaling, our understanding is still incomplete,
making it a priority to identify and target the mechanisms that confer resistance to therapy
[88, 141].
MicroRNAs in Melanoma
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MicroRNAs (miRs) are 17-24 nucleotide long, non-protein-coding RNAs that bind to
complementary sequences on messenger RNA (mRNA) molecules, inhibiting translation
and increasing degradation of the target transcripts. One miR has multiple mRNA targets,
allowing a single miR to regulate the expression of many genes, often converging on a
particular pathway or biological process. Through this mechanism, it is estimated that miRs
can directly regulate translation of approximately 60% of human genes, making them
important post-transcriptional regulators of gene expression [142]. MiRs have been
demonstrated to directly influence specific cellular functions including proliferation,
survival, metastasis and resistance to targeted therapy across multiple cancer types
including melanoma [134, 143-151]. In glioma, miR-124 and miR-138 exert immunemediated anti-tumor effects by inhibiting STAT3 signaling and reducing expression of
immune checkpoint molecules, while miR-142 and miR-155 play important roles in
macrophage and effector T cell responses against cancer [131, 135, 136, 152]. To date there
has not been a comprehensive analysis of the role of miRs in melanoma immunity.
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RESULTS
Characterizing the Immune Landscape of Melanoma
To identify candidate immunomodulatory microRNAs, our strategy was to compare
microRNA expression in the human skin cutaneous melanoma (SKCM) dataset from The
Cancer Genome Atlas (TCGA) with a selection of immune correlates: a) pathological
assessment of tumor infiltrating lymphocytes (TIL), b) cytolytic score comprising
Granzyme A and Perforin 1 gene expression levels and c) CIBERSORT, a bioinformatics
method using transcriptomic data to infer the composition of immune cells within a tumor
immune infiltrate [126, 153, 154]. We hypothesized that microRNAs with strong
associations with immune exclusion or infiltration would be compelling candidates for
further investigation as immunomodulatory genes. For this comparison, we first estimated
the immune infiltration status of 322 melanoma samples from the TCGA dataset using the
tumor microenvironment deconvolution tool CIBERSORT (LM22) (Figure 2.1 a). From
this analysis we can see the immune content of this melanoma dataset mostly consists of
macrophage and T-cell lineages. Specifically M0, M2 and M1 macrophage populations are
three of the five most abundant immune populations while CD8, follicular helper, CD4
memory and T regulatory cells comprise four of the eight most abundant immune
populations. Other less abundant components of the immune microenvironment by this
methodology include naïve and memory B cells, plasma cells, NK cells, monocytes and
mast cells. Other immune populations such as eosinophils, neutrophils, gamma delta T
cells and dendritic cells are estimated to be mostly absent from these tumors although there
are some exceptions to this. As the TCGA dataset consists of tumors from multiple disease
sites, and knowing that there is potential for differential immune involvement at
34
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Figure 2.1 Immune Profiling Reveals Significant Immune Populations in TCGA
Melanoma Tumors. CIBERSORT analysis of n TCGA melanoma samples from primary,
regional skin, regional lymph and distant skin metastases quantifies the abundance of
pertinent immune cell populations. Box and whisker plot (A) represent median, IQR and
min/max abundance of each immune population estimated by MCP counter. Outliers are
defined as ± 1.5 * the IQR beyond the upper and lower quartiles and represented by black
dots. Pie charts represent the average relative abundance of each immune population in
tumors from differing disease stage / sites.

36

different sites, notably lymph nodes, we compared the relative abundance of each immune
population across each disease site (Figure 2.1 b). Although we did previously observe
higher absolute immune scores in regional lymph tumors relative to other sites, the relative
abundance of each immune cell type remained remarkably stable across disease sites. Some
slight variation was observed, most notably when comparing the regional lymph and distant
skin tumors, where there are generally higher proportions of B cells. In the regional lymph
samples, this seems to be at the expense of macrophages, while in the distant skin samples
it seems to be at the expense of T-cells. However, since relative measures of abundance are
dependent variables and absolute abundance varies by disease site it is difficult to make
robust comparisons between immune markers across disease sites.
Previous analysis of TCGA melanoma samples revealed that immune markers including
LCK protein expression and histopathological assessment of immune infiltration
(Lymphocyte-score) were prognostic indicators for overall survival. We investigated if any
of the immune markers we had calculated had a similar prognostic value. To this end we
performed a survival analysis with each of the CIBERSORT immune estimates as well as
for CD8A mRNA expression and the cytolytic score which is derived from perforin and
granzyme mRNA expression (Figure 2.2). We also included LCK and the Lymphocyte
score from the original analysis. Our results replicated the previously published findings
that LCK and Lymphocyte Score were associated with increased overall survival (Hazard
ratio, log rank p; 0.28, 0.015 and 0.49, 0.057 respectively). In addition to this, four of our
immune markers also demonstrated some prognostic utility. The strongest results came
from the M1 macrophage gene signature (Hazard ratio = 0.35 (95%CI = 0.16-0.74) log
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Figure 2.2 Melanoma Immune Markers Are Associated with Improved Overall
Survival in TCGA Melanoma Samples. We measured survival outcomes in TCGA
melanoma patients based on the abundance of different immune features in their tumors.
(a) Kaplan Meier curves for each immune feature displaying curves for samples divided
into tertiles based on expression of each immune feature, using time to death as the event
value. Log rank p-value and hazard ratios ± 95% confidence intervals are shown for upper
and middle tertiles compared to lower tertile in each plot. * represents P-value < 0.05 **
represents P-value < 0.01 compared to the lowest tertitle in each plot.
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rank p=0.015). Interestingly, although their expression is correlated, the M2 macrophage
signature did not show any significant prognostic value (Hazard ratio = 0.69 (95% CI =
0.35-1.35) log rank p=0.56), highlighting the polarized biology of these differentiated
states of macrophages. Two other intuitive results were the prognostic value of the total
CIBERSORT score, the sum of all estimated immune populations in the tumour
microenvironment (hazard ratio = 0.49 (95% CI = 0.25-0.96) log rank p=0.045), and the
cytolytic score (hazard ratio = 0.47 (95% CI = 0.24-0.92) log rank p=0.023). Both of these
markers indicate a significant cytotoxic immune infiltrate. One counterintuitive result was
the positive prognostic indication of regulatory T cell abundance (hazard ratio = 0.4 (95%
CI = 0.19-0.8) log rank p=0.031, since we normally associate this population with negative
regulation of cellular immunity. This discrepancy may be due to infidelity of the
CIBERSORT algorithm, since FOXP3 is a classic marker of regulatory T cells but may
also be expressed during early activation of cytotoxic T cells, making it uncertain if we are
accurately counting the regulatory T cell population using this method.
Characterizing the microRNA landscape of melanoma:
The next step of this project was to identify microRNAs associated with microenvironment
features of melanoma, including the immune markers described above and also
transcriptomic markers of tumor purity and melanoma lineage markers. For this analysis
we correlated normalized microRNA counts from TCGA melanoma samples from all
disease sites with the markers described above (Figure 2.3) To visualize the pattern of
microRNA associations we plotted the correlation coefficients from each microRNA with
each microenvironment feature with hierarchical clustering in a heatmap (Figure 2.3 a).
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Figure 2.3 Melanoma MicroRNA Expression is Associated with Tumor
Microenvironment Composition. We examined the relationship between TCGA
microRNA expression and a panel of melanoma and immune markers. (a) A clustered
heatmap representing Spearman’s correlation coefficients between expression of each
microRNA and each melanoma or immune marker measured from transcriptomic data.
Major microRNA clusters are denoted on the track on the right of the heatmap. (b) Box
and whisker plot showing microRNA expression in TCGA samples (log2 median ±
interquartile range and IQR x1.5). (c)

Box and whisker plot showing microRNA

expression in melanoma cell lines (n=62) (log2 median ± interquartile range and IQR x1.5).
(d) A barplot comparing microRNA expression in TCGA samples and melanoma cell lines
to identify melanoma intrinsic microRNA expression. MicroRNAs that are expressed at
higher levels in tumor samples are blue. MicroRNAs that are expressed at higher levels in
cell lines are red.
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The most striking result from this analysis was the observation of five distinct clusters of
microRNA associations with broad categories of microenvironment markers. We named
these clusters sequentially from the top of the heatmap to the bottom. Cluster 1 contains
microRNAs predominantly correlated with expression of immune markers including Tcells, monocytes, NK cells, B cells, cytolytic score and the L-score of lymphocyte
infiltration, this cluster also had strong inverse correlations with LUMP and ESTIMATE
markers of tumor purity indicating that these microRNAs are expressed at higher levels in
melanoma samples where the microenvironment content is inflamed and melanoma
markers are diluted. We defined this cluster as the ‘Immune’ cluster. Cluster 2a contains a
mixture of relatively weak correlations of immune markers but also some stromal and
melanoma markers and is therefore classified as the ‘Intermediate’ cluster. Cluster 2b also
contains some weak correlations with immune markers and inverse correlations with
melanoma markers but is defined by the highest correlations with fibroblast and endothelial
cell signatures amongst any microRNAs in this dataset. We therefore classified this group
as the ‘Mesenchymal’ cluster. Cluster 3a appears to have the opposite associations with
cluster 2b, with high correlations with melanoma lineage markers, TYR, MLANA and
MITF with moderate correlations with LUMP and ESTIMATE markers of immune purity
and moderate inverse correlations with immune and stromal markers. Due to the strongest
associations with melanoma markers this group was classified as the ‘Melanoma’
microRNA cluster. The fifth and final cluster, 3b, shared similar characteristics to the
‘Melanoma’ cluster 3a but the strength of correlations was weaker and is therefore
classified as the ‘Intermediate Melanoma’ cluster. Since correlative analyses are sensitive
to biological variation we next repeated the analysis across sites of disease to understand
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Figure 2.4 Immune:MicroRNA Relationships Maintained Across Sites of Disease We
examined the relationship between TCGA microRNA expression and a panel of melanoma
and immune markers across 4 different sites of disease using heatmaps with supervised
clustering based on figure 2.3. (a) A heatmap representing Spearman’s correlation
coefficients between expression of each microRNA and each melanoma or immune marker
measured from transcriptomic data in primary melanoma biopsies (n=38). Major
microRNA clusters are denoted on the track on the left of the heatmap. (b) A heatmap
representing Spearman’s correlation coefficients between expression of each microRNA
and each melanoma or immune marker measured from transcriptomic data in regional skin
/ soft tissue biopsies (n=50). (c) A heatmap representing Spearman’s correlation
coefficients between expression of each microRNA and each melanoma or immune marker
measured from transcriptomic data in regional lymph node biopsies (n=155). (d) A
heatmap representing Spearman’s correlation coefficients between expression of each
microRNA and each melanoma or immune marker measured from transcriptomic data in
distant metastases (n=33).
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if the variation of microenvironment compositions affected our data (Figure 2.4). In this
analysis we supervised the clustering of our samples using the clusters obtained when
comparing all samples (Figure 2.3). Using this approach we can compare the integrity of
each microRNA cluster across disease sites. We observed that generally the clusters
remained consistent despite the relatively low numbers in the primary and distant
metastasis groups (n=38 and 33, respectively. We next investigated the individual
microRNA membership of these clusters. In the ‘Immune’ cluster we noted exclusive
membership of canonical immune-miRs with established roles in immune-biology such as
miR-155-5p, miR-142-5p, miR-146b-5p, miR-342-3p and miR-29c-3p. Interestingly these
microRNAs were also previously associated with the ‘Immune’ transcriptomic subset of
melanoma identified in the SKCM TCGA dataset. We also identified well defined
melanoma transcriptomic subset associated microRNAs in the ‘Melanoma’ cluster and
‘Stromal’ cluster. Specifically we identified miR-211-5p, miR-508, miR-509, miR-514a3p and miR-146a-5p in the ‘Melanoma’ cluster which associates with the “Keratin’
transcriptomic subset of melanoma and the ‘MITF-low’ transcriptomic subset associated
microRNAs miR-100-5p and miR-125b-5p in our ‘Stromal’ cluster. Taken together we
surmised that this methodology could effectively identify microRNAs associated with
immune infiltrated melanomas, melanomas with high stromal content and high purity
melanomas.
Identification of Immune-Associated MicroRNAs in Melanoma
Since immune content of melanomas has prognostic value, we hypothesized that the
microRNAs with strongest associations with immune infiltration may also have prognostic
values. To test this hypothesis we filtered microRNAs expressed in one hundred and
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Figure 2.5 Schematic of Immuno-MicroRNA Identification in TCGA Samples. We
used this work flow to define ‘Immuno-MicroRNAs’ as microRNAs significantly
associated with at least one immune feature in TCGA melanoma samples.
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Figure 2.6. Identification of Immuno-MicroRNAs in Melanoma TCGA. We compared
MicroRNA expression with 24 transcriptomic, protein and histopathological markers of
immune infiltration and activation in 123 high purity regional lymph node biopsies from
the melanoma TCGA. (a) A clustered heatmap representing 50 microRNAs with a
significant association (Spearman correlation coefficient > 0.5, FDR adjusted P-value
<0.1) with at least one immune marker.
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twenty-three high purity, metastatic melanomas with the strongest positive and negative
associations with immune markers tor additional survival analysis (Figure 2.5). Using this
approach, we classified 50 out of 817 microRNAs (Spearman’s rho <-0.4, >0.4, FDR
adjusted p<0.1) as ‘Immune- Associated MicroRNAs’ (Figure 2.6). We then performed
survival analysis on the ‘immune-associated microRNAs using Cox’s proportional hazards
and Kaplan Meier survival analysis (Figure 2.7). Five out of fifteen (10%) microRNAs had
a statistically significant association (log-rank p<0.05) with overall survival in regional
lymph node TCGA melanoma samples. Of these, the microRNA with the strongest
association with overall survival was miR-146b-3p (hazard ratio = 0.22 (95% CI = 0.10.46), log-rank p-value <0.0001), which is a stronger prognostic power than the best
immune marker (LCK hazard ratio = 0.28). The other four microRNAs were miR-155-5p,
miR-1976, miR-361-3p, miR-142-3p (Hazard ratio, log-rank p-value; 0.39, 0.0017; 0.32,
0.0059; 0.35, 0.04; 0.44, 0.047 respectively).
Identification of Validated Targets of Immune-MicroRNAs with Known Roles in
Melanoma Immuno-Biology
To identify rational and testable mechanisms that could potentially explain the association
of our microRNAs with immune infiltration or exclusion, we first filtered microRNAs
based on their expression in a panel of 62 melanoma cell lines followed by searching for
previously experimentally validated targets with known roles in melanoma immunebiology. Having identified fifty ‘immune-associated’ microRNAs we stratified them based
on their expression in melanoma cell lines versus melanoma tissue. The rationale for this
was the hypothesis that melanoma-specific microRNA regulation of gene expression could
modulate immune infiltration, for example through cytokine secretion, and we wanted to
50
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Figure 2.7 Immuno-MicroRNA Expression Associated with Improved Overall
Survival in TCGA Melanoma Patients. We measured survival outcomes in TCGA
melanoma patients based on the expression of immune-associated microRNAs in their
tumours. (a) Kaplan Meier curves for each microRNA displaying curves for samples
divided into tertiles based on expression of each microRNA, using time to death as the
event value. Log rank p-value and hazard ratios ± 95% confidence intervals are shown for
upper and middle tertiles compared to lower tertile in each plot. * represents P-value <
0.05, ** represents P-value < 0.01, *** represents P-value <0.001, compared to the lowest
tertitle in each plot.
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separate these microRNAs from the microRNAs that are predominantly expressed in the
infiltrating immune cells that arise as a consequence rather than a cause of inflammation
(Figure 2.3 b-d). Using this approach we identified fourteen microRNAs with 1 or more
experimentally validated immune targets, among these there were 9 microRNAs with 1 or
more experimentally validated immune target that had been directly implicated or had a
rational connection to mechanisms of melanoma immune evasion (Table 2.1).
MiR-508-3p Regulation of NF-kB and Downstream Immune Modulatory Genes
Of the microRNAs with validated immune targets, the first that we investigated was miR508-3p, which was associated with lower immune infiltration and lower scores of immune
cytotoxicity in the TCGA SKCM dataset, suggesting an immunosuppressive effect on the
tumor microenvironment. The interaction between hsa-miR-508-3p and the NF-κB genes
NFKB1 and RELA has been described previously in gastric carcinoma, including the
modulation of downstream NF-κB target genes [155]. NF-κB signaling regulates a large
number of immunomodulatory genes and is the leading candidate to explain the
immunosuppressive phenotype associated with hsa-miR-508-3p. Our first experiment to
test if miR-508-3p regulated NF-kB activity was an in-silico analysis of miR-508-3p
correlation with NF-kB target genes, using the target genes of non miR-508-3p targeted
transcription factors STAT1 and MYC as negative controls (Figure 2.8 a). In this analysis
we observed a slight but statistically significant (p=0.0009) inverse correlation of NF-kB
target genes compared to negative controls, indicating that melanomas with higher miR508-3p expression have less NF-kB activity. To test if the reported miR-508-3p repression
of NF-kB existed in melanoma, we measured NF-kB protein expression by Western blot
after transient transfection of a melanoma cell line (MDA 2333) with a miR-508-3p mimic
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Table 2.1 Identification of Validated Targets of ‘Immuno-MicroRNAs’ With Known
Roles in Melanoma Immuno-Biology. We compared the validated targets of microRNAs
identified in Figure 2.6 in MiRTarBase. The number of validated targets with an immune
ontology are counted and specific genes with published roles in melanoma immunity are
listed.
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Figure 2.8 MiR-508 is Associated with Reduced Expression of NFkB Target Genes
and Inhibits Secretion of IL-6 in Melanoma Cell Lines. We tested the effect of miR508-3p expression on NFkB and NFkB target gene expression in melanoma. (a) Dotplot
representing Spearman’s correlation coefficients of miR-508-3p with curated gene-sets
representing the transcription targets of the NFkB, MYC and STAT1 in TCGA melanoma.
(b) Western blot showing NFkB p50/p105 staining and GAPDH loading control. Samples
from left to right are 1nM non-specific miR mimic, 1nM miR-508-3p mimic, 10nM nonspecific miR mimic, 10nm miR-508-3p mimic. (c) Barplot representing intensity of NFkB
p50 staining relative to GAPDH in each sample. (d) Barplot representing copies of miR508-3p relative to reference miR in MDA2333 melanoma cells measured by qPCR after
transfection with different doses of miR-508-3p mimic. (e) Barplot representing copies of
IL-6 mRNA transcripts relative to reference gene in MDA2333 melanoma cells after
transfection with different doses of miR-508-3p mimic. (f) Barplot representing levels of
secreted IL-6 from conditioned media from MDA2333 cell line cultures after transfection
with non-specific microRNA mimic and miR-508-3p mimic.
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(Figure 2.8 b,c). When we quantified NF-kB protein levels we observed reduced NF-kB
p50:GAPDH ratios with both 1nM and 10nM doses of miR-508-3p mimics compared to
non-specific mimic controls (0.94 vs 1.41, 0.97 vs 1.76 respectively). Of the many NF-kB
targets, we selected IL-6 as a strong candidate for melanoma regulation of the immune
microenvironment. We subsequently tested our melanoma cell line for IL-6 mRNA
expression by qPCR and found a significant reduction after transfection with 10nM miR508-3p mimic compared to 10nM non-specific mimic treated cells (p<0.01) (Figure 2.8 e).
In addition we tested IL-6 protein secretion in conditioned media from melanoma cell lines
under the same transfection conditions (Figure 2.8 f). Taken together these data suggest
that miR-508-3p negatively regulates NF-kB expression and function in melanoma, and
protein expression of downstream NF-kB transcription targets such as IL-6 can be
regulated by miR-508-3p modulation.
MiR-509-3p Modulates Expression of HLA Expression in Melanoma
The next microRNA of interest that we investigated in vitro was miR-509-3p. Similarly to
miR-508-3p, miR-509-3p was inversely correlated with expression of immune markers in
melanoma, and in HLA had a feasible mechanism of action to elicit an immunosuppressive
phenotype. For this microRNA we measured HLA-ABC expression by flow cytometry in
a panel of four melanoma cell lines after transient transfection with miR-509-3p mimic
(Figure 2.9). We observed significant repression of HLA expression in two out of four
miR-509-3p mimic treated cell lines compared to non-specific mimic treated cells
(p<0.001).
Multiple Immune-Associated MicroRNAs Modulate Cytokine Secretion In Vitro
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Figure 2.9 Exogenous Expression of MiR-509 Downregulates HLA Expression in 2/4
Melanoma Cell Lines.

Figure 2.9 Exogenous Expression of MiR-509 Downregulates HLA Expression in 2/4
Melanoma Cell Lines. We transiently transfected the melanoma cell line MDA 2333 with
miR-509-3p to test it’s effect on HLA expression, previously validated as a miR-509-3p
target. (a) Schematic of experimental design, transfected cells allowed 72 hours for
exogenous microRNA effects to manifest. (b) Boxplot representing median fluorescence
intensity of HLA-ABC antibody staining in multiple melanoma cell lines after transient
transfection with either a non-specific microRNA mimic or miR-509-3p mimic. ***
represents p-value < 0.001
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Figure 2.10 Exogenous Expression of Immune Associated Melanoma MicroRNAs
Regulate Secretion of Immuno-regulatory Cytokines

59

Figure 2.10 Exogenous Expression of Immune Associated Melanoma MicroRNAs
Regulate Secretion of Immuno-regulatory Cytokines. We transiently transfected the
melanoma cell line MDA 2333 with immune-associated microRNAs miR-17-5p, 93-5p
and 155-5p to test their effects on secretion of previously validated cytokine targets. (a)
Schematic of experimental design, transfected cells allowed 72 hours for exogenous
microRNA effects to manifest. (b) Boxplot representing duplicate immunoassay
quantification of secreted VEGF in conditioned media from transiently transfected cells
with either a non-specific microRNA mimic or miR-17-5p or miR-93-5p mimic. (c)
Boxplot representing duplicate immunoassay quantification of secreted IL-1b, IL-6 and
VEGF in conditioned media from transiently transfected cells with either a non-specific
microRNA mimic or miR-155-5p.
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Having demonstrated the potential for immune associated microRNAs to modulate
immunomodulatory genes in vitro we tested three additional microRNAs with
experimentally validated cytokine targets. We selected miR-17-5p, miR-93-5p which are
both reported to target VEGF and miR-155-5p which is reported to target Suppressor of
Cytokine Signaling 1 (SOCS1) and measured cytokine release by multiplex immunoassay
(Figure 2.10) In both miR-17-5p and miR-93-5p mimic treated melanoma cell culture we
observed reduced secretion of VEGF compared to non-specific mimic transfected cells. In
miR-155-5p mimic treated cells we observed a dramatic increase in secretion of IL-1b, IL6 and VEGF.
MiR-155 Regulates Melanoma Cell Sensitivity to T-cell Killing In Vitro
Finally, we selected miR-155-5p, due to its dramatic in vitro effect on cytokine secretion,
for further immune analysis. We used a chromium release assay to measure melanoma cell
death after co-culture with MART-1 specific T-cells to measure specific T-cell killing of
melanoma cells (Figure 2.11). We demonstrated specificity for MART-1 positive, HLAmatched cell lines, with cell death only observed in cell lines that were MART-1 positive
and HLA-02 positive. Cell lines that were either MART-1 negative or HLA mismatched
were not affected. We tested four MART-1, HLA-02 positive melanoma cell lines, either
transfected with a miR-155-5p mimic or inhibitor compared to non-specific mimics and
inhibitors and found a significant protective effect i.e. reduced cell death when cells were
treated with miR-155-5p mimics, in Mel526, MDA2333, MDA2400 and MDA2508
(p=0.01, <0.0001, <0.0001, <0.0001 respectively).
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Figure 2.11 Exogenous Expression of Immune Associated Melanoma MicroRNAs
regulate Melanoma Cell Sensitivity to T-Cell Killing In-Vitro. We performed T-cell
killing assays on a panel of 4 melanoma cell lines with transient transfection of miR-1555p mimic and inhibitor to determine the effect of miR-155-5p expression on sensitivity of
melanoma cells to T-cell killing. (a) Dotplots representing % tumor cell death of positive
controls, Mel256 (HLA matched and positive for T-cell cognate antigen – MART1), and
negative controls, A375 and A2058 (MART-1 negative or HLA mismatched) (b) Dotplot
representing % mel526 cell death under different effector : target cell ratios (c) Dotplot
representing relative % melanoma cell death versus transfection control for each cell line
when transfected with either miR-155-5p mimic or inhibitor.
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SUMMARY
We have completed a detailed description of the immune composition of metastatic
melanoma tissue using a selection of bioinformatics tools based on mRNA sequencing
data. We showed that the proportions of different immune populations as estimated by
CIBERSORT were relatively stable across disease sites, although absolute immune content
was increased in lymph node biopsies. Expression of certain transcriptomic markers
including the cytolytic score and total CIBERSORT scores were shown to have prognostic
value when measuring overall survival of melanoma patients, although this was not as
powerful as LCK protein expression.
We were able to identify 50 microRNAs whose expression were significantly correlated
with the abundance of at least one measured immune feature of melanoma tumors.
Amongst these 50 immune-associated microRNAs we identified 5 that had significant
prognostic value, including miR-146b-3p which outperformed LCK protein expression
based on a univariate Cox’s-proportional hazard model. There are limitations of this model
including the assumption of proportional hazard over time but also making direct
comparisons of hazard ratios determined in separate univariate models. Additional
statistical analysis including multivariate Cox’s proportional hazard models and also
parametric survival models would be desirable for a more robust validation of these
markers as prognostic biomarkers.
We then sought to elucidate any immune-modulatory mechanisms that these microRNAs
may regulate in melanoma. We identified 14 microRNAs with previously validated
immune targets. Of these we selected miR-508-3p (Targets NF-kB), miR-509-3p (Targets
HLA-A), miR-17-5p (Targets VEGF), miR-93-5p (Targets VEGF), miR-155 (Targets
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SOCS1) for further investigation. In each case we were able to show microRNA regulation
of their respective targets. In the case of miR-155-5p we were able to dramatically increase
secretion of IL-1b, IL-6 and VEGF in vitro through exogenous expression of miR-155-5p.
Exogenous expression of miR-155-5p also had a profound protective effect against T-cell
killing.
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CHAPTER THREE
MICRORNA AND mRNA PROFILING OF PRE-PD1 INHIBITOR TREATED
MELANOMA BIOPSIES
ABSTRACT
Immunotherapy has dramatically improved the outcome for many melanoma patients,
however, approximately half of patients do not receive durable responses. The mechanisms
of resistance to immunotherapy are only partly understood and effective therapies to
overcome them are urgently required.
MicroRNAs are major post-transcriptional regulators of gene expression and the aberrant
expression and activity of microRNAs is involved in multiple oncogenic processes. In
melanoma, these processes include proliferation, resisting cell death and activation of
invasion and metastasis. There is also evidence that microRNAs can also regulate the tumor
microenvironment and response to immunotherapy. To date, this has not been extensively
studied in humans and could reveal important mechanisms of immune evasion that could
be targeted therapeutically.
In this chapter we performed a genomic analysis of pre-PD1 treated melanoma biopsies to
identify transcriptomic profiles associated with response. We also quantified microRNA
expression from the same biopsies to identify microRNA profiles associated with response
to therapy and also their relationship with transcriptomic profiles of response.
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INTRODUCTION
Response to anti-PD-1 immunotherapy is determined by a complex relationship between
tumor cells, the tumor microenvironment (TME) and the host immune system. Several
transcriptomic studies of PD-1 treated melanoma patients have already been published and
have revealed distinct gene expression profiles associated with patients who responded to
therapy [90, 92, 156-160]. Transcriptomic analyses of melanoma tumors prior to anti-PD1 treatment have identified gene expression signatures that predict responder and nonresponder patients with better accuracy than single biomarkers. Understanding the
mechanisms that regulate response-associated transcriptomic profiles are therefore of
significant clinical interest, as they may offer novel biomarker and therapeutic approaches
to overcoming resistance.
MicroRNAs are key regulators of gene expression and are associated with disease
progression and drug resistance in multiple cancer types including melanoma. We therefore
hypothesized that microRNAs may be associated with immune evasion via their regulation
of gene expression and that this would be measurable in melanoma biopsies from patients
undergoing anti-PD-1 immunotherapy.
In this study, we performed genomic analysis of pre-treatment tumor samples from patients
treated with anti-PD-1 immunotherapy and identified two transcriptionally distinct
subgroups associated with clinical response. Further characterization of the two groups
using miRNA sequencing revealed novel miRNAs associated with response. Additionally,
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we also performed analyses mapping mRNA:microRNA interactions in the TME and their
associations with response to PD-1 treatment.
RESULTS
Patient Cohort:
Twenty-nine patients with AJCCv8 stage III or IV melanoma undergoing PD-1 immune
checkpoint blockade at the University of Texas MD Anderson Cancer Center were
included in this study (Table 3.1). All patients had cutaneous-type or unknown primary
melanoma. Twenty (67%) patients were male, nine (31%) patients were female. Seventeen
(59%) patients had progressed on prior ipilimumab treatment. Pre-treatment biopsies were
consented and collected under institutional-review-board-approved protocols [2012-0846
and LAB00-063] no more than 6 months prior to commencement of pembrolizumab or
nivolumab therapy and with no intervening therapy or documented continuous progression
during a brief period of intervening therapy. Best Overall Response (BOR) was calculated
using RECIST 1.1 criteria. Fourteen (48%) patients were classified as receiving clinical
benefit (BOR; stable disease >6months, complete or partial response), while Fifteen (52%)
patients were classified as not receiving clinical benefit (BOR; progressive disease).
Measured Median Progression-Free Survival (PFS) in the non-responder group was 83
days (range; 20-NA), median PFS was not reached in the responder group (range; 257NA). Lesion specific responses were available for thirteen (45%) patients where incisional
biopsies were performed (Figure 3.1, Table 3.1).
Unsupervised Clustering Identifies Response-Associated Transcriptomic Profiles
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Figure 3.1. Schema of Pre-PD1 Treatment Melanoma Cohort. We collected melanoma
specimens from 30 patients before they started anti-PD-1 checkpoint blockade for
molecular analysis. (a) Schema showing the study design, with collections and RNAsequencing of pre-treatment biopsies prior to treatment with anti-PD1 checkpoint
blockade.
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Table 3.1 Pre-PD1-Treated Melanoma Patient Characteristics
Characteristic
RNA sequencing

PD-1i No Clinical
Benefit
14

Small RNA sequencing
Sex

PD-1i Clinical
Benefit
15

9

13

Male
Female
Melanoma Type

12 (86%)
2 (14%)

9 (56%)
7 (44%)

In situ
Cutaneous unspecified
Superficial spreading

6 (43%)
1 (7%)

7 (44%)
2 (13%)

-

-

Nodular
Acral lentiginous

1 (7%)
1 (7%)

2 (13%)
1 (6%)

Mucosal
Unknown primary

5 (36%)

2 (13%)

Disease stage (AJCCv8)
IIIa/b
IIIc/d

1 (7%)
3 (21%)

2 (13%)

IVa
IVb
IVc

10 (71%)

2 (13%)
1 (6%)
11 (69%)

528.5 (349-1786)

432 (78-1090)

Lentigo malignant melanoma

IVd
Serum LDH (U/L; Median,
Range)
Prior ipilumumab

Yes
7 (50%)
No
7 (50%)
Best Overall Response (BOR, RECIST 1.1)
CR
PR
SD
PD
PFS (median, range; days)

11 (69%)
5 (31%)

6 (43%)
6 (43%)
2 (14%)

-

1205 (257-1644)

16 (100%)
80.5 (20-90)
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We first sought to identify transcriptomic profiles associated with response to anti-PD-1
treatment using RNA-sequencing (RNA-seq) on biopsies from pre-PD1-treatment
melanoma patients. We first used consensus clustering to determine optimum unsupervised
clustering of all samples, based on expression of the 1500 most variable genes (Figure 3.2).
We generated consensus clustering matrices for a range of cluster solutions (k=2-6) to find
the optimum number of mRNA clusters in the dataset (Figure 3.2 a-e). To quantify the
accuracy of the different clustering solutions we measured cumulative distribution
functions (CDF) of each consensus matrix (Figure 3.2 f-g). It is apparent that each increase
in the number of clusters incrementally increases the CDF of the consensus matrix although
there are diminishing returns with each additional cluster, there is still no obvious inflection
point that would definitively guide our choice of an optimal clustering solution. Indeed
with the 6 cluster solution two of the clusters only include individual samples, indicating
the granularity that is resolved by the consensus clustering is to the level of inter sample
variability rather than shared transcriptomic characteristics of multiple samples. This
paradigm is highlighted in the tracking plot indicating cluster membership of each sample
across clustering solutions (Figure 3.2 h). The two-cluster model using this method
effectively separated responding and non-responding patients: Cluster 1 containing 12/14
clinical benefit patients and cluster 2 containing 11/15 non-clinical benefit patients (Figure
3.3, Notably, these samples clustered independently of melanoma subtype (p=0.825),
gender (p=0.688) and receipt of previous immunotherapy (p=0.13) (Table 3.1) Increasing
the number of clusters increased the Area Under the Curve (AUC) of the Cumulative
Distribution Function (CDF) curves (K2 = ~0.5, K4 = ~0.9) but the additional clusters did
not further separate samples by response or melanoma subtype and due to low numbers
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Figure 3.2 Consensus clustering of RNA-sequencing data
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Figure 3.2. Consensus Non-Negative Matrix Factorization Clustering of Pre-PD-1
Treated Melanoma RNA-seq Samples. We used non-negative matrix factorization to
identify unsupervised transcriptomic subsets within our RNA-seq dataset. (a-e) cNMF
clustering of all samples using the 1500 genes with highest standard deviation for k=2 to
k=6. (f) Plot of the cumulative distribution function (CDF) curves or each clustering
solution k2:k6. (g) Plot representing the change in the area under the curve of each CDF
curve in f, with each additional k. (h) Tracking plot showing the cluster membership of
each sample (x-axis) for each k clustering solution (y-axis).
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Figure 3.3 Characterisation of pre-PD1 Treatment Biopsies
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Figure 3.3 Characterisation of pre-PD1 Treatment Melanoma Biopsies. We collected
melanoma biopsies from 30 pre-PD1 treated melanoma patients. (a) A clustered heatmap
representing the 50 genes with the most significant differential gene expression
differences between mRNA ‘Cluster 1’ and ‘Cluster 2’ as identified by consensus nonnegative matrix factorisation (25 highest in ‘Cluster 1’ and 25 highest in ‘Cluster 2’).
Values displayed are gene-normalized Z-scores. Tracks above heatmap display sample
information including the mRNA cluster memebership, clinical benefit, lesion-specific
response and melanoma subtype. (b) A volcano plot displaying all DESEQ2 differential
expression results from mRNA sequencing, plotting log2-foldchange against negative
log10 p-values. Top differentially expressed genes are coloured red and labeled with gene
names. (c) Hallmark Gene-Set Enrichment Analysis (GSEA) of differentially expressed
genes identified by DESEQ2 with a normalized enrichment score >1.5 identifies
enrichment of 4 genesets in mRNA cluster 1 (associated with improved clinical benefit)
and 12 genesets in mRNA cluster 2 (associated with reduced clinical benefit).
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would reduce the power of additional analysis. We were able to measure lesion specificresponses for 13 incisional biopsies. Since response to immunotherapy can be
heterogeneous and sampling from individual lesions may not be representative of the whole
disease, we compared the lesion specific response with the overall response and plotted
those with our heatmap of gene expression analysis (Figure 3.3 a). Of the lesion specificresponses these only one had a mismatched classification where the lesion responded
differently to the overall disease course. In order to further explore the biological
significance of the two clusters we had identified we compared differential gene expression
between the clinical benefit and non-clinical benefit clusters, identifying 641 genes with
an FDR adjusted p-value <0.1. To explore the biological significance of the differential
gene expression we performed Gene set enrichment analysis (GSEA) of these 641
significantly differentially expressed genes. This identified 4 gene sets enriched in the
Responder cluster (FDR<0.001), including Interferon Gamma Response and Interferon
Alpha Response, indicative of a functioning host immune reponse, while the NonResponder cluster was enriched for 12 gene sets (FDR <0.001), including MYC and E2F
transcription factor targets, Oxidative Phosphorylation and DNA repair genes (Figure 3.3
c).
Response-Associated Clusters Enriched for Immune Markers
As response to immunotherapy is closely related to pre-existing immune features of the
TME, we measured the levels of immune markers in our samples and compared expression
across our response-associated clusters. We calculated the cytolytic score, the immunepredictive score (IMPRES), and estimates of the cellular composition of our samples from
transcriptome data using MCP counter (Figure 3.4 a -d)[153, 160, 161]. Of these markers,
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Figure 3.4 Immune Features of pre-PD1 Treatment Biopsies
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Figure 3.4 Immune Characterisation of Pre-PD-1 Treated Melanoma Biopsies. We
calculated immune scores based on transcriptomic expression data for each sample with
MCP counter and cytolytic scores based on Perforin 1 and Granzyme A expression. (a)
Expression of MCP counter microenvironment cell composition estimates compared
between biopsies from patients who did or did not receive clinical benefit from anti-PD-1
checkpoint blockade. (b) Expression of tumour cytolytic scores compared between patients
who did and did not receive clinical benefit from anti-PD-1 checkpoint blockade. We also
compared MCP counter scores (c) and cytolytic scores (d) between patients who had or
had not received prior ipilimumab therapy to test the effect of a prior immunotherapy on
the composition of the immune microenvironment.
Data points are colour coded by individual patient response and groups are compared
using Wilcoxon’s rank-sum test.
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there was significant enrichment of T-cells (p=0.01), cytotoxic lymphocytes (p=0.02), Bcells (p=0.05) and neutrophils (p=0.04), as estimated by MCP counter, in the clinical
benefit cluster. The cytolytic, IMPRES and MCP-counter-CD8-T-cell score also trended
higher in the clinical benefit cluster but did not reach statistical significance. A similar
pattern of immune-marker enrichment was observed when comparing samples strictly by
RECIST response. In this comparison T-cells (p=0.02), cytotoxic lymphocytes (p=0.04)
and B cells (p=0.02) were again higher in responding samples, as were CD8 T-cells
(p=0.05), NK cells (p=0.05), cytolytic score (p=0.03) and IMPRES (p=0.01). The higher
neutrophil signature that we observed in the responder-cluster was not seen in this
comparison (p=0.65). To test if prior immunotherapy with Ipilimumab had an effect on
responses or to the composition of the tumour microenvironment, we repeated our response
and immune microenvironment analysis with prior ipilimumab therapy as the predictor
variable. We found that prior ipilimumab therapy was not associated with RECIST
response (p=0.59) or the response associated clusters in this cohort. To test if prior
Ipilimumab treatment had an impact on the immune microenvironment in our samples, we
compared immune marker expression in 17 samples that had prior Ipilimumab exposure
with the 12 samples that were immunotherapy naïve. Overall, only the NK cell signature
was significantly differentially expressed, being lower in Ipilimumab treated samples
compared to immunotherapy naïve samples (p=0.04) (Figure 3.4 c-d). The cytotoxic
lymphocyte and IMPRES signatures also trended lower in Ipilimumab treated samples
although this was not statistically significant (p=0.07 and p=0.06 respectively). It is
difficult to determine in this study if these differences in immune markers are a direct result
of Ipilimumab’s biological activity on the tumour-immune infiltrate or whether Ipilimumab
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treatment has selected for tumours with a specific immune microenvironment, however we
did not observe any significant effect on outcome to subsequent PD-1 therapy in this
cohort.
Transcriptomic Clusters Associated with Distinct MicroRNA Expression Profiles
Having identified two response-associated clusters from our transcriptomic data, we
wanted to identify microRNAs that were associated with these clusters and to describe the
relationship between microRNA and mRNA expression in our dataset. We first used
DEseq2 to identify individual microRNAs that were differentially expressed in the
responder and non-responder clusters. This analysis identified 5 microRNAs enriched in
the responder cluster and 10 microRNAs enriched in the non-responder cluster (padj<0.1)
(Figure 3.5a,c). Of these 15 microRNAs, miR-31-5p, 203a-3p and miR-205-5p were the
top candidates for further analysis, with a log fold change (>2) between the responder and
non-responder clusters and experimental evidence of biological activity (miRbase).
Second, as microRNA family members exert co-operative regulation through shared
sequence homology, we considered microRNA family members that individually may not
have met the inclusion criteria for the individual microRNA analysis but cumulatively may
be of biological significance. In this analysis we identified 3 microRNA families enriched
in the responder cluster and 2 microRNA families enriched in the non-responder cluster
(padj<0.1) (Figure 3b). These microRNA families included miR-31, miR-203 and miR205 in concordance with our individual microRNA analysis. In addition, the miR-515
family was highly enriched in the responder cluster (lfc=7.8 padj<0.001), although no
single miR-515 family members were detected in our initial microRNA analysis due to
their low individual expression levels. As there was not 100% concordance between our
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Figure 3.5 MicroRNA Differential Expression Analysis
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Figure 3.5 MicroRNA Differential Expression Analysis in Pre-PD-1 Treatment
Melanoma Biopsies. We performed microRNA sequencing from RNA extracted from the
biopsies of melanoma patients prior to treatment with anti-PD-1 checkpoint blockade. In
this analysis we used DESEQ2 to compare the differential expression in microRNAs in
samples that we had classified by their mRNA cluster membership, as above. (a) A volcano
plot representing log2 fold changes and negative log 10 p-values for each microRNA
compared using DESEQ2. Values on the left of the plot are enriched in samples belonging
to mRNA cluster 2, associated with resistance to anti-PD-1 therapy, and values on the right
are enriched in samples belonging to mRNA cluster 1, associated with sensitivity to antiPD-1 therapy. (b) A volcano plot representing log2 fold changes and negative log 10 pvalues for each microRNA family (sum of counts of each microRNA family member)
compared using DESEQ2. Values on the left of the plot are enriched in samples belonging
to mRNA cluster 2, associated with resistance to anti-PD-1 therapy, and values on the right
are enriched in samples belonging to mRNA cluster 1, associated with sensitivity to antiPD-1 therapy. (c) Heatmap representing per sample expression of the top differentially
expressed microRNAs in samples from mRNA cluster 1 vs cluster 2. Values are row
normalized z-scores from variance stabilized log2 transformed read counts. Sample cluster
membership and clinical benefit is shown in the tracks above the heatmap.
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transcriptomic clusters and clinical benefit, we also repeated this analysis with a direct
comparison of samples from patients who did receive clinical benefit vs those that did not
receive clinical benefit (Figure 3.6). Using this approach we confirmed some microRNAs
that we previously identified as significantly differentially expressed between
transcriptomic clusters, including miR-205-5p and miR-31-5p.
Experimental Validation of Response-Associated MicroRNAs
Although none of the microRNAs that we identified in our differential expression analysis
had previously been implicated in tumour immunology, we sought to determine if they
played a role in melanoma cell sensitivity to T-cell killing in-vitro. For these assays we
first measured endogenous expression of miR-31-5p, miR-200b-3p and miR-205-5p in a
panel of four melanoma cell lines (Mel-526, MDA-2333, MDA-2400 and MDA-2580).
We found very low or undetectable levels of our microRNAs of interest in all four cell
lines (figure 3.7 b). Transient transfection of microRNA mimics dramatically and
consistently increased levels of specific microRNA in each cell line allowing us to compare
the effect of increased microRNA expression on melanoma sensitivity to T-cell killing
(figure 3.7 c). We measured melanoma cell death by chromium release assay after a 4 hour
co-culture with MART-1 specific T-cells in our four melanoma cell lines (Figure 3.7 d).
We observed no differences in melanoma cell death with miR-31-5p in any of the four cell
lines we tested. With miR-200b-3p we noted one out of the four cell lines (MDA 2333)
had a slight but statistically significant reduction level of cell death, indicating exogenous
miR-200b-3p conferred some resistance to T-cell killing. However the remaining three cell
lines had unchanged sensitivity to T-cell killing suggesting a cell specific effect. With miR205-5p we also saw a slight but statistically significant protective effect against T-cell
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Figure 3.6 MicroRNA Differential Expression Analysis Based on Clinical Benefit
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Figure 3.6 MicroRNA Differential Expression Based on Clinical Benefit (a) A volcano
plot representing log2 fold changes and negative log 10 p-values for each microRNA
compared using DESEQ2. Values on the left of the plot are enriched in samples from
patients who did not receive clinical benefit from anti-PD-1 immunotherapy and values on
the right are enriched in samples from patients who did receive clinical benefit from antiPD-1 therapy. (b) Summary statistics from top differentially expressed microRNAs from
a, identifying three microRNAs with significantly high expression with large
log2foldchanges (>2) and FDR <0.1)
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Figure 3.7 Effect of Exogenous Expression of Response-Associated MicroRNAs on
Melanoma Cell Line Sensitivity to T-Cell Killing
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Figure 3.7 Effect of Exogenous Expression of Response-Associated MicroRNAs on
Melanoma Cell Line Sensitivity to T-Cell Killing. We performed T-cell killing assays
on a panel of 4 melanoma cell lines with transient transfection of microRNAs of interest to
measure the effect of increased microRNA expression on sensitivity of melanoma cells to
T-cell killing. (a) Schema. (b) Barplots representing endogenous expression of each
microRNA of interest in each cell line relative to stably expressed reference microRNAs.
(c) Barplots representing levels of exogenous miR-205-5p 72hrs post transfection in a
panel of melanoma cell lines relative to stably expressed reference microRNAs. (d)
Dotplots displaying percentage cell death from each cell line under each microRNA
condition after 4hr co-culture with T-cells. Significant differences vs control are depicted
by a black bar.
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killing in two of the four cell lines tested (Mel526 and MDA2333). In this case the
remaining two cell lines also had an unchanged sensitivity to T-cell killing.
Summary
In this chapter we used RNA and microRNA sequencing to profile the tumors of a cohort
of twenty-nine pre-PD1 inhibitor treated melanoma patients. Using an unsupervised
approach to classifying tumors based on their mRNA expression we were able to identify
two transcriptomic groups that closely aligned with responses to immunotherapy. Among
these two groups we were able to identify enrichment of particular gene sets associated
with response and resistance to therapy. These included an enrichment of genes involved
in interferon gamma response in responding tumors and an enrichment of genes involved
in oxidative phosphorylation in non-responding tumors. We also identified transcriptomic
immune markers were also enriched in responding tumors, including a CD8 T-cell
signature.
Having established transcriptomic groups of samples that corresponded to response, we
identified microRNAs differentially expressed between the two groups, identifying eight
differentially expressed microRNAs. Of these we selected three with the highest tissue
expression for in vitro functional validation, miR-31-5p, miR-200b-3p and miR-205-5p.
We used a T-cell killing assay with melanoma cells transfected with these microRNAs to
identify any effects on sensitivity to T-cell killing. Using this assay we found a modest
protective effect of miR-205-5p in 2/4 melanoma cell lines indicating this microRNA may
help melanomas evade immune destruction and resist PD1 immune checkpoint blockade.
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CHAPTER FOUR
NETWORK ANALYSIS OF MELANOMA TISSUE AND CELL LINES
REVEALS MICRORNA NETWORKS RELEVANT TO PD1
IMMUNOTHERAPY
This Chapter is based on the following work
-

Robert Szczepaniak Sloane, Michael A. Davies, Scott E. Woodman, Miles C.
Andrews, Jennifer A. Wargo. Identification of MicroRNA-mRNA Networks in
Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.
Manuscript Submitted

ABSTRACT
Metastatic melanoma is a deadly malignancy with historically poor outcomes to therapy.
Immuno-Oncology (IO) agents targeting immune checkpoint molecules such as Cytotoxic
Lymphocyte Antigen-4 (CTLA-4) and Programmed Death-1 (PD-1) have revolutionized
melanoma patient care, achieving significantly improved response rates and remarkable
long-term survival. Despite the vast improvement in treatment options, roughly half of
melanoma patients do not receive long-term clinical benefit from IO therapies and there is
an urgent need to understand and mitigate mechanisms of resistance. MicroRNAs are key
post-transcriptional regulators of gene expression and can regulate many aspects of cancer
biology including immune evasion. In this study we used network analysis to define two
core microRNA-mRNA networks in melanoma tissues and cell lines corresponding to
‘MITF-low’ and ‘keratin’ transcriptomic subsets of melanoma. We then compared
expression of these core microRNAs in pre-PD-1 inhibitor treated melanoma patients and
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observed that higher expression of miR-100-5p and miR-125b-5p were associated with
significantly longer overall survival compared to low expressing tumors. These findings
suggest that miR-100-5p and 125b-5p are potential markers of response to PD-1 inhibitors
and further experimental investigation of these microRNA-mRNA interactions may yield
further insight into melanoma resistance to PD-1 inhibitors.
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INTRODUCTION
Immune checkpoint inhibitors targeting Cytotoxic T-lymphocyte associated protein 4
(CTLA-4) and Programmed cell death 1 (PD-1) have radically improved survival outcomes
for metastatic melanoma patients. Treatment with PD-1 inhibitors result in long-term
survival for ~40% of patients, compared to ~20% with CTLA-4 inhibition and just 5% with
the prior standard of care, dacarbazine [26, 162-164]. However, a significant subset of
melanoma patients do not receive clinical benefit from these treatments. Understanding the
factors that influence response to immune checkpoint blockade is therefore necessary for
new therapeutic strategies and to improve patient care.
Translational studies by our lab and others have identified several key determinants of
response to PD-1 inhibition; intuitively these include the presence of PD-1 positive T-cells
and the expression of programmed cell death 1 ligand 1 (PD-L1) in the tumor
microenvironment (TME) and a high tumor mutation and immunogenic neoantigen burden
[157, 165-167]. In addition, numerous cellular and genomic parameters have been
associated with response including distinct transcriptomic profiles, PTEN status,
composition of the gut microbiome and the composition of the TME including levels of Bcells, and fibroblasts [45, 156-158, 160, 168-171]. Despite these advances in our
understanding, improvements in clinical practice are yet to be realized, and improved
predictive biomarkers and therapeutic strategies are still required to improve patient care.
MicroRNAs are major post-transcriptional regulators of gene expression, directly binding
and repressing translation of approximately 60% of human mRNAs [142]. MicroRNA
regulation of gene expression has an established role in many of the hallmarks of cancer
biology [172]. In melanoma this includes angiogenesis, EMT, invasion and resistance to
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targeted therapy [173-176]. Furthermore, a comprehensive study of The Cancer Genome
Atlas (TCGA) Skin and Cutaneous Melanoma (SKCM) dataset defined three
transcriptomic subsets of melanoma (‘Keratin’, ‘MITF-low’ and ‘Immune’) each with a
distinct microRNA expression profile [126]. Pre-clinical studies in multiple cancer types
including melanoma have provided evidence of microRNA-mediated immune regulation
that can affect sensitivity to immune surveillance [134, 135, 137]. However, melanoma
microRNA expression has not been extensively studied in the context of clinical
immunotherapy responses. We therefore sought to map the landscape of microRNA
expression in melanoma and identify relationships with immunotherapy outcomes.
In this study we used a network analysis approach to identify a core set of microRNAs, in
TCGA tumors and patient derived melanoma cell lines, with strong associations with
melanoma gene expression [177]. Using this approach we identified two distinct
microRNA networks, broadly similar to previously identified patterns of microRNA
expression in melanoma. We subsequently examined the relationship of these microRNAs
with survival outcomes in pre-PD-1-treatment melanoma biopsies and identified miR-1005p and miR-125b-5p, from the same microRNA network, were associated with survival
benefit in PD-1 treated patients.
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RESULTS
Landscape of microRNA-mRNA associations in TCGA Melanomas
To build a network of relationships between the miRnome and the transcriptome we first
comparing Spearman’s correlation coefficients of all microRNAs and all mRNAs reads
from the TCGA melanoma datasets. All microRNAs with at least one mRNA correlation
(Spearman’s rho <-0.4, >0.4) were plotted with hierarchical clustering in a heatmap to
explore groups of microRNAs with common patterns of gene expression (Figure 4.1a).
Using this approach we can identify two main clusters of microRNA-mRNA correlations,
each with two major sub-clusters. On the left, the larger cluster contains 14 microRNAs all
of which were previously identified as associated with the ‘keratin’ melanoma
transcriptomic subset and includes the canonical ‘keratin’ melanoma microRNA, miR-2115p, On the right of the heatmap with ten microRNAs, we observed microRNAs associated
with the ‘MITF’low’ (miR-125b-5p, miR-100-5p) and ‘Immune’ (miR-146b-3p, miR146b-5p, miR29b-3p, miR-223-3p) melanoma transcriptomic subsets. When comparing
these subsets, it is easy to identify subclusters with almost perfectly opposite gene
expression associations, most notably the ‘keratin’ microRNAs, including miR-211-5p
which appears to mirror the ‘MITF-low’ microRNAs, miR-100-5p and miR-125b-5p.
Similarly, the ‘Keratin’ microRNAs miR-17-3p, miR-17-5p and miR-92a-3p mirror the
‘Immune’ microRNAs. It is interesting to note that we can identify relationships between
the existing three-transcriptomic subset classification of melanomas that may not have been
predicted. For example while the dichotomy between ‘keratin’ and ‘MITF-low’ microRNA
is established, it is interesting to note that the ‘keratin’ microRNAs separate into two subclusters, one of which more closely mirrors
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Figure 4.1: Network Analysis of Global MicroRNA:mRNA Associations in TCGA
Melanoma Samples.
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Figure 4.1: Network Analysis of Global MicroRNA:mRNA Associations in TCGA
Melanoma Samples. (a) Clustered heatmap representing Spearman’s rho values of all
microRNA:mRNA correlations observed in TCGA melanoma samples where each
microRNA has an inverse correlation (Spearman’s rho <-0.4) with expression of at least 1
mRNA. (b) Adjacency matrix representing the number of mRNA inverse correlations
shared by each microRNA in the TCGA microRNA:mRNA network.
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‘MITF-low’ microRNAs while the other subset more closely mirrors the ‘Immune’ subset
of microRNAs. It is tempting to speculate that the one subset of ‘keratin’ microRNAs
including miR-211-5p is central to maintaining the ‘keratin’ phenotype while the other
subset is involved in other biological processes that may associate with immune infiltration
or exclusion.
To further investigate the cluster relationships from the heatmap we plotted the number of
inverse correlations shared between each microRNA identified in Figure 4.1a in an
adjacency matrix (Figure 4.1b). In this analysis it is easy to identify the same cluster
membership described in the heatmap, with the ‘keratin’ microRNAs forming the largest
cluster with an apparent tiered membership, with miR-508-3p, miR-508-5p, miR-509-3p
and miR-514a-3p sharing the most number of mRNA associations (87-111 shared
associations) while three of the ‘keratin’ microRNAs, miR-17-5p, miR-92a-3p, miR-173p, form a distinct subcluster with relatively few shared associations with any other
‘keratin’ microRNAs (0-5 shared associations). The remaining ‘keratin’ microRNAs have
significant overlap with the miR-508-3p cluster although with fewer overall shared mRNA
associations with other ‘keratin’ microRNAs (0-61 shared associations). The remaining
‘MITF-low’ and ‘Immune’ melanoma subset microRNAs again form separate and distinct
clusters.
We then used a network analysis approach to quantify inverse correlations of microRNA
and mRNA expression in the TCGA melanoma dataset. We identified 1739 microRNAmRNA associations comprising 74 microRNAs inversely correlated with expression of at
least 1 mRNA (Spearman’s rho <-0.4). Of these 74 microRNAs, 19 were associated with
>20 mRNAs each, accounting for 1521/1739(87%) of the total microRNA-mRNA inverse
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correlations. Bipartite and unipartite network projections of the top 19 microRNAs
identifies three distinct network hubs corresponding to the ‘Keratin’, ‘MITF-low’ and
‘Immune’ transcriptomic-subset-associated-microRNAs previously identified in this
TCGA cohort and, unsurprisingly due to the overlapping methodology, shares similarities
to the data represented in Figure 4.1 (Figure 4.2). The largest of these hubs consists of the
TCGA ‘Keratin’ associated microRNAs; miR-211-5p, 146a-5p, 181a-2-3p, 506-3p, 5083p, 508-5p, 509-5p, 509-3-5p, 514a-3p, 17-3p, 17-5p, 92a-3p and 185-5p (Fig 1a, b, Table
S2). This network hub accounts for 1153/1739 (66%) of all observed microRNA-mRNA
inverse correlations and also contains the microRNAs with the highest degree centrality
(miR-211-5p - 293), betweenness centrality (miR-29b-3p, 17-3p, 211-5p, 185-5p - 42.5,
25.5, 24.5, 23.5, respectively), and eigenvector centrality (miR-508-3p, 514a-3p, 508-5p,
509-3p [1, 1, 0.93, 0.92, respectively]). The second largest network hub, by number of
microRNA-mRNA associations (266/1739, 15%), consists of the TCGA ‘MITF-low’
microRNAs; miR-100-5p and 125b-5p. This hub is separate from the rest of network, with
zero shared mRNA associations with other microRNAs and therefore scores low (<0.01)
on eigen, betweeness and closeness network centrality. We also observed that MITF was
among the inversely correlated mRNAs within this network, consistent with the previous
characterization of these microRNAs in the TCGA. The third largest network hub, by
number of microRNA-mRNA associations (102/1739, 6%) consists of the TCGA
‘Immune’ microRNAs; miR-29b-3p, 146b-3p, 146b-5p and 223-3p. This network hub only
shares scores low for measures of network centrality
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Figure 4.2: Network Analysis of Global MicroRNA:mRNA Associations in TCGA
Melanoma. Inverse correlations of microRNA and mRNA pairs were calculated to identify
potential microRNA regulated gene networks. (a) Bipartite network projection displaying
the 19 microRNAs (red) with highest numbers (>20) of inversely correlated (Spearman’s
rho <-0.4) mRNAs (blue) within all TCGA melanoma samples, identifies three distinct
microRNA:mRNA network hubs. (b) Unipartite network projection displaying the mRNA
inverse correlations shared by each microRNA (higher number of correlations indicated by
connecting line thickness). MicroRNAs are colour coded by their previous association with
specific TCGA transcriptomic subsets. (c) Gene-Set Enrichment Analysis of all mRNAs
inversely correlated with ‘Keratin’ transcriptomic subset associated microRNAs. (d)
Gene-Set Enrichment Analysis of all mRNAs inversely correlated with ‘MITF-Low’
transcriptomic subset associated microRNAs.
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(<0.1) indicating very few shared mRNA associations with other microRNAs in the
network. To understand the biological significance of these networks we performed gene
set enrichment analysis (GSEA) on the mRNAs that were inversely correlated with each
network (Fig 4.2 c, d). The most significant enrichment of genes in the ‘keratin’ microRNA
cluster was in the epithelial to mesenchymal transition (EMT) gene set (33 genes, FDR q
= 2.36E-24), consistent with prior experimental evidence of miR-211-5p inhibition of EMT
in melanoma. The most significant enrichment of genes in the ‘MITF-low’ microRNA
cluster was in oxidative phosphorylation (15 genes, FDR q = 1.39E-11). In parallel with
the findings of individual mRNA associations, there was also no overlap of gene set
enrichment between the ‘keratin’ and ‘MITF-low’ microRNA associated genes, indicating
that these networks represent functionally distinct regulatory networks. Genes that were
inversely correlated with the ‘Immune’ microRNAs were not found to be enriched in any
gene-sets.
Landscape of microRNA-mRNA Associations in Patient Derived Melanoma Cell Lines
To verify our findings from the TCGA samples, we repeated our analysis in a panel of 61
early passage melanoma cell lines obtained from melanoma TIL harvests performed at The
University of Texas MD Anderson Cancer Center. Our first observation from this analysis
was the far stronger correlation of microRNA and mRNA expression in melanoma cell
lines compared to melanoma tissue, presumably due to the reduced complexity of cell
culture conditions allowing greater resolution of melanoma specific transcription. This
allowed us to increase our correlation coefficient threshold to 0.6 from 0.4 in the TCGA
melanoma analysis. We identified 4489 unique microRNA-mRNA associations
comprising 81 microRNAs inversely correlated with expression of at least 1 mRNA
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(Spearman’s rho <-0.6) (Figure 4.3). All microRNAs with at least one mRNA correlation
(Spearman’s rho <-0.6, >0.6) were plotted with hierarchical clustering in a heatmap to
explore groups of microRNAs with common patterns of gene expression (Figure 4.3a).
Although much larger than the heatmap generated with the TCGA data, the structure is
relatively simple, with two main clusters of mRNAs and three clusters of microRNAs. On
the left, the larger microRNA cluster contains fifty-nine microRNAs including the ‘keratin’
microRNAs that we identified in the TCGA. This large microRNA cluster has strong
inverse correlations with the largest mRNA cluster indicating involvement in repression of
a large subset of genes. The second prominent cluster on the right of the heatmap is a much
smaller cluster of 14 microRNAs including the ‘MITF-low’ microRNAs miR-100-5p and
miR-125b-5p identified in the TCGA analysis. This cluster of microRNAs has strong
inverse correlations with the smaller mRNA cluster in contrast to the first microRNA
cluster. This is a repeat of the ‘keratin’ and ‘MITF-low’ dichotomy that we observed in the
TCGA dataset. The third cluster of consists of 35 microRNAs that seem to have an
intermediate association with the two mRNA clusters. In total we observed 2/2 ‘MITFlow’, 10/13 ‘Keratin’ and 1/4 ‘Immune’ associated microRNAs that we identified in the
TCGA dataset. We further investigated the relationships between the microRNAs
identified in this analysis using an adjacency matrix visualizing the number of inverse
mRNA correlations shared by each microRNA, filtered to include the top 18 microRNAs
with the highest individual mRNA associations (Figure 4.3b). This plot again highlights
the dichotomy of ‘keratin’ and ‘MITF-low’ microRNAs in melanoma, with many of the
same microRNAs identified in the TCGA analysis repeated here, including miR-211-5p,
miR-100-5p and miR-125b-5p.
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Figure 4.3: Network Analysis of Global MicroRNA:mRNA Associations in Melanoma
Cell Lines. (a) Clustered heatmap representing Spearman’s rho values of all
microRNA:mRNA correlations observed in melanoma cell lines where each microRNA
has an inverse correlation (Spearman’s rho <-0.6) with expression of at least 1 mRNA. (b)
Adjacency matrix representing the number of shared mRNA inverse correlations shared by
each microRNA in the melanoma cell line microRNA:mRNA network.
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For network analysis in the cell line dataset we repeated our filter of the initial 81
microRNAs used for the adjacency matrix. The top 18 microRNAs were associated with
>100 mRNAs each, accounting for 2748/4489 (61%) of the total microRNA-mRNA
inverse correlations. Bipartite and unipartite network projections of the top 18 microRNAs
identified two distinct network hubs (4.4 a,b). These two network hubs shared common
characteristics with the ‘Keratin’ and ‘MITF-low’ hubs identified in the TCGA dataset.
The ‘MITF-low’ network hub comprised the same two microRNAs, miR-100-5p and miR125b-5p and accounted for 308/4489 (7%) of the total microRNA-mRNA inverse
correlations in this dataset. In agreement with our TCGA analysis, we observed that MITF
was among the inversely correlated mRNAs within this network. This hub is again
completely separate from the rest of the network, with zero shared mRNA associations
with other microRNAs and therefore scores low (<0.01) on eigen, betweeness and
closeness network centrality. The larger hub accounted for 2440/4489 (50%) of the total
microRNA-mRNA inverse correlations in this dataset and shared some similarities with
the ‘keratin’ hub from the TCGA analysis, including the presence of miR-17-3p, 185-5p
and 211-5p, but did not exclusively contain microRNAs from the TCGA ‘Keratin’
transcriptomic subset (6/16 ‘Keratin’, 2/16 ‘Immune’ and 8/16 unaffiliated to any TCGA
transcriptomic subset). We again performed GSEA on the mRNAs inversely correlated
with each network. In the larger network we identified striking similarities with the
‘keratin’ network in the TCGA analysis, sharing 6 of the top 10 enriched gene sets,
including EMT, UV_Response_DN, Apical_Junction, TNFA_Signalling_via_NFkB,
Hypoxia and TGF_Beta_Signalling (Table S6). The GSEA of mRNAs inversely correlated
with the ‘MITF-low’ microRNA

104

105

Figure 4.4: Network Analysis of Global MicroRNA:mRNA Associations in Melanoma
Cell Lines. Inverse correlations of microRNA and mRNA pairs were calculated to identify
potential microRNA regulated gene networks. (a) Bipartite network projection displaying
the 18 microRNAs (red) with highest numbers (>100) of inversely correlated (Spearman’s
rho <-0.6) mRNAs (blue) within all TCGA melanoma samples, identifies two distinct
microRNA:mRNA network hubs. (b) Unipartite network projection displaying the mRNA
inverse correlations shared by each microRNA (higher number of correlations indicated by
connecting line thickness). MicroRNAs are colour coded by their previous association with
specific TCGA transcriptomic subsets. (c) Gene-Set Enrichment Analysis of all mRNAs
inversely correlated with ‘Keratin’ transcriptomic subset associated microRNAs. (d)
Gene-Set Enrichment Analysis of all mRNAs inversely correlated with ‘MITF-Low’
transcriptomic subset associated microRNAs.
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network also shared 2/10 enriched genesets with the TCGA ‘MITF-low’ network including
Estrogen_Response_Early and Adipogenesis.
PD-1 Treated Patient Cohort
Having identified prominent microRNA-mRNA networks in melanoma tumors and cell
lines, we asked if any of the microRNAs from these networks were related to
immunotherapy outcomes in pre-PD1 treated melanomas. We compared expression of the
19 microRNAs with the highest degree centrality in the TCGA bipartite network analysis
in the pre-PD-1-treatment biopsies of 22 stage III/IV melanoma patients, of whom 10
received clinical benefit and 12 did not. We observed significantly higher expression of
both miR-100-5p (median log2 counts: 12.48 vs 11.25, p-value = 0.036) and miR-125b-5p
(median log2 counts: 17.35 vs 15.49, p-value = 0.025) in the tumors of patients who
received clinical benefit compared to those who did not receive clinical benefit (p=0.025,
p=0.36, respectively) (Figure 4.5, Table 4.1). Although no other microRNAs were
significantly differentially expressed, we did note that miR-146a-5p, which has been
implicated as a negative regulator of immune activation in vivo, was slightly elevated in
the tumors of patients who did not receive clinical benefit (median log2 counts: 19.05 vs
18.13, p-value = 0.28) [30425059]. We then performed survival analysis using Cox’s
proportional hazard model and Kaplan Meier analysis (Figure 4.5 a, d-g). The survival
analysis showed low hazard ratios for both miR-100-5p (HR (95%CI): 0.5 (0.3-0.85)
p=0.01) and miR-125b-5p (HR (95%CI):0.51 (0.29-0.9) p=0.02) (Figure 4.5 a). High
melanoma expression of miR-100-5p and miR-125b-5p were both shown to predict
improved progression-free survival (log-rank test p=0.02, p=0.01, respectively) and overall
survival (log-rank test p=0.05, p=0.05, respectively).
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Table 4.1 Melanoma Pre-PD1 Treated Patient Characteristics
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Figure 4.5: Survival Analysis of Melanoma MicroRNAs in Pre-PD-1-Treated
Melanoma Biopsies. MicroRNA sequencing was performed on 22 Pre-PD-1-treated
melanoma biopsies, variance-stabilised-log2-transformed counts were generated using
DESEq2. (a) A forest plot displaying hazard ratios ± 95% confidence intervals from
univatiate Cox’s proportional hazard analysis of each of the 19 microRNAs with the
highest degree centrality in bipartite network analysis of TCGA microRNA:mRNA
expression. (b-c) Boxplots comparing variance-stabilised-log2-transformed counts of miR100-5p and miR-125b-5p in melanoma biopsies from patients who did not receive clinical
benefit from anti-PD-1 immunotherapy versus those who did receive clinical benefit.
Boxplots display median, interquartile range and whiskers representing 1.5 x the
interquartile range. (d-g) Kaplan Meier curves displaying the time to PFS or OS for patients
with biopsies with high (above median) compared to low (below median) expression of
miR-100-5p or miR-125b-5p.
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Discussion
We identified three core microRNA-mRNA networks in melanoma tumors that broadly
corresponded with previous observations of ‘Keratin’, ‘MITF-low’ and ‘Immune’
transcriptomic subsets in the TCGA SKCM dataset [126]. Further investigation of these
networks confirmed previous findings about the roles of these microRNAs, including the
prominence of miR-211-5p within the ‘keratin’ transcriptomic subset of melanoma and a
strong enrichment of epithelial to mesenchymal genes, including AXL and ZEB1, which
were inversely correlated with miR-211-5p expression. This supports previous evidence
for the regulatory role of miR-211 in EMT-like processes in melanoma [174]. Similarly we
found miR-100-5p and miR-125b-5p formed an independent network hub and were
inversely correlated with MITF expression, mirroring the association of these microRNAs
with ‘MITF-low’ melanomas from previous TCGA analysis [126]. The strong depletion of
OXPHOS genes associated with the MITF-low network is also supported by prior evidence
for the role of miR-125b and MITF as regulators of mitochondrial metabolism [178, 179].
The correlation analysis within the melanoma cell line dataset resulted in a substantially
higher number of microRNA-mRNA pairs allowing us to increase the correlation
coefficient threshold (<-0.6) and also the number of inverse correlations (>100) required
for inclusion in our network analysis. The increased sensitivity to microRNA-mRNA
interactions is likely due to the sampling of high purity cell lines with consistent culture
conditions compared to the variability inherent in whole tumors with unpredictable
stromal, immune and metabolic variation.
The network analysis in the melanoma cell lines shared broad similarities with the TCGA
network with a high degree of overlap in terms of individual microRNA-mRNA
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associations and also in GSEA of those mRNAs. The most obvious agreement between
datasets occurred with miR-125b and miR-100-5p network, with no overlap with other
microRNA-mRNA pairs and inverse correlation with MITF expression. One notable
difference in this network was the absence of enrichment of OXPHOS genes inversely
correlated with miR-100-5p and miR-125b-5p. It is possible that this difference is due to
the significant differences in metabolic requirements between cell culture and the TME,
but it is also possible that these metabolic differences are attributable to other components
of the TME such as monocytes [178, 180, 181] . The larger microRNA-mRNA network
identified in cell lines shared many characteristics with the ‘keratin’ microRNA network
identified in the TCGA analysis, with a core of the same ‘keratin’ melanoma-subsetassociated microRNAs including miR-211-5p. This network also shared enrichment of
6/10 gene sets with the ‘keratin’ TCGA network including EMT genes such as AXL and
ZEB1.
To identify microRNAs associated with PD-1 checkpoint blockade outcomes, we
compared microRNA expression in pre-treatment melanoma biopsies from patients who
did or did not receive clinical benefit from therapy. We focused on those microRNAs that
had the strongest degree centrality scores from our TCGA network analysis, hypothesizing
that microRNAs associated with specific gene expression profiles would most likely be
associated with differential responses. Using Cox’s univariate proportional hazard model
we found both ‘MITF-low’ microRNAs from our network analysis, miR-100-5p and miR125b-5p, were associated with clinical benefit in this cohort. Interestingly previous
research has implicated expression of these microRNAs, in a panel of others, with myeloid
derived suppressor cell (MDSC) mediated resistance to immune checkpoint inhibitors. It
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is unclear from their methodology and published data what the individual predictive power
of each microRNA within the panel was. It is important to note that this microRNA data
was obtained through peripheral plasma sampling and is therefore unclear how comparable
it is with tumor expression data [182]. Although there is limited experimental evidence for
the role of these microRNAs in melanoma immunity, it should be noted that OXPHOS was
the most significantly inversely correlated gene set identified in the ‘MITF-low’
microRNA-mRNA. There is some recent evidence for the role of OXPHOS and melanoma
immune evasion [183-185]. In this study, melanoma brain metastases with lower OXPHOS
gene expression were associated with higher immune infiltration. We can therefore
speculate that ‘MITF-low’ microRNAs and associated inverse correlation of OXPHOS
gene expression may influence melanoma immunity, although this would require further
investigation.
Beyond the ‘MITF-low’ microRNAs, we found a trend towards higher miR-146a-5p
expression in melanomas that did not receive clinical benefit, although this result did not
reach statistical significance, possibly due to the small cohort size. This aligns with a preclinical model of miR-146a-5p in melanoma association with resistance to immunotherapy
and also highlights a potential dichotomy between ‘keratin’ and ‘MITF-low’ associated
microRNAs and immunotherapy responses [137].
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CHAPTER FIVE
DISCUSSION AND FUTURE DIRECTIONS
DISCUSSION
Summary of all MicroRNA Analyses
We undertook parallel and partially overlapping approaches to identification of
microRNAs implicated in melanoma immunity and resistance to anti PD-1
immunotherapy. We were able to identify multiple microRNAs by each method, however
not every microRNA was included in every analysis. To summarize the data we collected
for each microRNA, I have included a table (Table 5.1). There are few microRNAs that we
were able to collect comprehensive experimental and clinical data from because they were
primarily identified by different aims within this project and we did not have time to crossvalidate each microRNA, particularly experimentally with cytokine secretion and T-cell
killing assays. Below is a discussion of our findings for each methodology used and the
microRNAs subsequently identified. Briefly these can be classified into three categories;
1- MicroRNAs with strong prognostic value in TCGA data and experimental evidence for
roles in regulating immune pathways and processes but no evidence of differential
expression in clinical specimens (miR-155-5p). I discuss below the reasons why miR-1555p may not be identified as predictive in anti-PD-1 treated patients due to opposite effects
in different cell types in the tumour microenvironment and further analysis and
experiments that could resolve this 2. MicroRNAs with evidence of differential expression
in clinical specimens and some experimental evidence of immune modulation but little
association with survival and no association with immune markers or prognostic value in
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TCGA (miR-205-5p, miR-200b). 3. MicroRNAs with strong associations with survival in
anti-PD-1 treated melanoma patients but with no association with immune markers or
prognosis in TCGA (miR-100-5p, miR-125b-5p). These microRNAs are of great interest
as discussed below as they may represent a subtype of melanoma with a distinct phenotype
with as-yet undescribed sensitivity to anti-PD-1 immunotherapy and/or a potential
predictive biomarker in this setting. I describe in the future directions section experiments
that could be performed to elucidate this.
Identification of Immune-Associated MicroRNAs in TCGA Melanoma Samples
A comprehensive analysis of TCGA melanoma tissue identified 5 microRNAs with strong
associations with immune infiltration and rational validated immune targets that may
explain these associations. We were able to demonstrate in melanoma cell lines that these
microRNAs can regulate their predicted immune targets in this disease and may offer
potential mechanisms for modulating the melanoma tumor microenvironment. Of these
microRNAs miR-155-5p had the most profound biological effects in vitro.
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Table 5.1 Summary of MicroRNA Analyses
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MiR-155-5p
High expression of miR-155-5p was correlated with immune markers in TCGA melanoma
samples and was associated with improved OS in those patients. Sequencing data from
melanoma and immune cell lines showed that miR-155 was expressed in melanoma cells
and in activated T-cells. While there is abundant evidence for the activating role of 155-5p
in T-cells, its immune role in melanoma cells is poorly defined. The data from this assay
suggests that miR-155-5p in tumor cells could contribute to immune evasion which would
contradict the survival benefit associated with miR-155-5p expression in the TCGA. Based
on this data I would reason that improved OS survival associated with miR-155-5p in
TCGA patients is due to a) miR-155-5p expression and activity in immune cells and/or b)
a tumor suppressor role in melanoma that is more significant than its effect on immune
evasion. Further investigation of the differential effects of miR-155-5p is required to
determine the cell-specific effects in the tumor microenvironment (see future directions)
Identification of MicroRNAs Associated with Clinical Response to PD1 Inhibitors
Using RNA and small RNA sequencing we were able to identify 8 microRNAs with
significant differential expression between melanoma patients who did or did not receive
clinical benefit from PD1 inhibitors, furthermore we were able to experimentally validate
these microRNAs in a T-cell-melanoma co-culture assay: miR-31-5p was overexpressed
in responding lesions and therefore hypothesized that is would sensitize melanoma cells to
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T-cell killing. With this assay I did not observe any effect of miR-31-5p on sensitivity to
T-cell killing in any of the 4 cell lines tested. This data suggests that miR-31-5p expression
in melanoma cells does not affect direct interactions with cytotoxic T-cells and its
association with response to immunotherapy may be through a separate mechanism such
as mediating immune infiltration or through activity in other cell types such as immune
cells. miR-200b-3p was overexpressed in non-responding lesions to PD-1 checkpoint
blockade and therefore I hypothesized miR-200b-3p would protect melanoma cells from
T-cell killing. This was the case in 2/4 cell lines. miR-205-5p, like miR-200b-3p, was
overexpressed in non-responding lesions to PD-1 checkpoint blockade. Again I
hypothesized this microRNA would protect melanoma cells from T-cell killing and this
was the case in 3/4 cell lines. The data from miR-200b-3p and miR-205-5p suggests that
individually they can regulate sensitivity to T-cell killing in some but not all melanomas.
Interestingly, while miR-200b-3p shows activity in 2/4 and miR-205-5p shows activity in
3/4 cell lines, every cell line tested was affected by at least one of these two microRNAs.
Further investigation of the mechanism of action for both of these microRNAs may reveal
important immunoregulatory pathways that could be exploited for melanoma
immunotherapy. Since only a modest effect on sensitivity to T-cell killing was observed
it is important to identify the cell type or types within the tumor microenvironment that
these microRNAs are expressed in and therefore biologically active in as described in the
future directions section below. The T-cell killing assay we used was a reductive
experiment with only a fraction of the factors present in the tumor microenvironment and
it is therefore necessary to use a more complete model of tumor immunity. With this
information we can design syngeneic mouse models with conditional expression of our
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microRNAs of interest in the relevant cell types. Using this model it would be possible to
identify how the tumor microenvironment is altered depending on expression of each
microRNA by measuring tumor, immune and stromal cell populations in models with high
or low target microRNA both with and without immunotherapy intervention. Furthermore,
specific effects on gene expression could be measured with microRNA-mRNA reporter
assays and downstream protein quantification by western blot or a multiplex method such
as RPPA. Measuring the dependence of any phenotype on the expression of specific
proteins targeted by our microRNAs of interest may reveal the mechanisms that these
microRNAs can regulate immunotherapy responses.
After extensive analysis of the microRNA sequencing data in our melanoma patient cohort,
we recognized that using the binary clinical benefit endpoint was very sensitive to changes
in sample classification. For example, when we included lesion specific responses we
changed the definition of one sample between clinical benefit and non-clinical benefit. In
a cohort of 22 patients, this had significant effects on the differential expression analysis.
We also noted significant differences in differential expression analysis when we compared
samples based on their membership of transcriptomic groups or strictly by RECIST
response. We therefore determined that identifying microRNAs associated with PFS and
OS outcomes after anti-PD-1 therapy was a more robust method than associations with
response. This is regarded as the gold standard for immunotherapy due to the atypical
kinetics of immunotherapy with regard to tumor responses as traditionally measured by
RECIST. Furthermore, we reasoned that we should limit our model to microRNAs that we
know are significantly associated with gene expression in melanoma to improve the
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statistical power of our analysis, considering the small cohort of PD1 inhibitor treated
patients.
To this end I used network analysis to identify microRNA-mRNA associations in
melanoma tumors (SKCM TCGA) and in melanoma cell lines (MD Anderson Melanoma
Cell Line Cohort). I then used Cox’s proportional hazard model to identify associations
with PFS and OS in our pre-PD1 treated melanoma patient samples from the top 18
microRNAs identified in the network analysis. This approach determined that miR-100-5p
and miR-125b-5p were significantly associated with improved OS and PFS in patients
treated with anti-PD-1 therapy. Furthermore these two microRNAs represent a distinct
microRNA-mRNA network that does not overlap with other microRNA-mRNA networks
identified in our samples.
Further clinical and experimental validation of these targets are warranted to translate these
findings into potential clinically useful targets.
FUTURE DIRECTIONS
Although we have extensively studied expression of microRNA and their associations with
immune features in melanoma and identified several specific microRNAs with statistical
associations with response and survival outcomes to PD-1 checkpoint blockade, the
mechanisms that underlie these associations remain poorly defined and warrant further
investigation. Here I will discuss the research that I think is the logical continuation of this
project to address the questions we have raised and demonstrate clinical relevance.
Resolution of Tissue Level Sequencing
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One of the challenges of RNA sequencing of RNA extracted from homogenized tumor is
the inability to attribute the signal we see to specific components of the tumor
microenvironment. We know that different cell lineages present in the tumor
microenvironment have distinct RNA and microRNA expression profiles and the data we
receive from whole tumor sequencing is an average of the values across multiple cell types
including immune, stromal and tumor cells. Further complicating the data we see is the
variation in tumor microenvironment composition between patients and even in tumors
from the same patient and even in different locations within the same tumor. We are
therefore unable to definitively attribute the source of differential expression of any of the
genes we identify; do they represent a genuine biological difference within melanocytes,
stromal cells or immune cells between responding or non-responding lesions or are they
merely acting as biomarkers for the abundance of these different cell types which also
governs response?
To answer this question we need to separately sequence the different constituents of the
tumor microenvironment. Single cell sequencing would provide the highest resolution
although the current technical and financial constraints on this technology may prohibit a
significant study [186, 187]. For the purposes of resolving expression between cell types,
single cell resolution is likely not required and could be achieved by FACS enumeration
and sorting cells by expression of lineage markers and sequencing the resulting
populations. Other in situ gene expression methods may also be useful to study intra
tumoral heterogeneity [188].
As we have shown here, the activity of certain genes can lead to competing phenotypes
within the tumour microenvironment. For example miR-155-5p is an established marker
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of immune activation and expressed in high levels in cytotoxic T-cells. Conversely, we
have shown that expression of miR-155-5p in melanoma tumour cells has an immuneprotective effect. Tissue level resolution of miR-155-5p is therefore unable to differentiate
potentially beneficial expression in T-cells compared to possible detrimental expression in
melanoma cells. Thus, the absence of miR-155-5p enrichment in either responding or nonresponding melanoma tumours is inconclusive and requires further investigation.
Additionally, I believe this would help improve the power of the statistical analysis of other
microRNAs including miR-100-5p and miR-125b-5p which are both known to be
expressed in tumour and stromal cell populations such as fibroblasts, which may be
immunosuppressive, in contrast to our dataset which shows that tissue expression of miR100-5p and miR-125b-5p is associated with improved overall survival, indicating
contrasting immune effects in different components of the tumor microenvironment [182].
Identifying the source of each microRNA will allow us to investigate the mechanism of
that microRNA in the appropriate cell type.
Experimental Validation of Clinically Relevant MicroRNAs
While we were able to identify numerous microRNAs associated with different immune
features and with PD-1 inhibitor responses in melanoma, we have only been able to
perform limited functional validation of these genes, particularly those that were identified
in the clinical cohort, which took longer to identify. Future experiments using miR-100-5p
and miR-125b-5p conditional knockout cell lines in vitro and in vivo models of tumor
immunity will be required to elucidate the role these microRNAs have in melanoma
immunity.
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There are several outstanding questions concerning the role of miR-100-5o and miR-125b5p in melanoma immunity: Primarily, are miR-100-5p and miR-125b-5p directly
regulating genes that are mediating resistance/sensitivity to immunotherapy or are they
biomarkers of a differential immune phenotype i.e. are these microRNA associations with
PD-1 response correlative or causative. We could initially test the effect of these
microRNAs on gene expression and determine if these microRNAs are key regulators of
this gene expression profile or a dependent covariate incidentally associated with the
observed transcriptomic profile. Although we performed comprehensive correlation
analysis of these microRNAs with mRNA expression in melanoma and tissue, it is not
sufficient to conclude that these genes are directly regulated, indeed there was no
enrichment for predicted miR-100-5p or miR-125b-5p targets within the inversely
correlated mRNA network that we identified, suggesting any association with these
specific genes is indirect. To test this we must show that miR-100-5p and miR-125b-5p
expression regulates target gene expression in melanoma (either in melanoma cell lines or
other microenvironment populations). This can be tested using reporter assays for
microRNA-mRNA binding which can empirically measure the mRNAs that are bound in
melanoma by these microRNAs. Measuring downstream protein expression as described
above could provide further evidence for actual miR-100-5p / miR-125b-5p regulation of
specific protein expression in melanoma. Further, if as suspected these microRNAs do not
directly regulate the target genes, we can focus on their interaction with other regulators of
gene expression such as transcription factors. Functional validation of these microRNAs
with an immune endpoint should also be investigated. This can initially be the assays we
have established during this project such as multiplex cytokine secretion and or T-cell
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killing assays in vitro. Additional in vivo experimental models as described above would
also be of use, testing the role of these microRNAs in melanoma cells and also in stromal
cell populations in a more complete model of tumor immunity.
Furthermore in the event that specific modulation of these microRNAs does not affect
tumour immunity, it would be of interest to address if the phenotype they are associated
with i.e. a mesenchymal like melanoma had experimental differences to immune therapy.
These experiments could be wide ranging, including screening a large panel of melanoma
cell lines with melanocytic vs mesenchymal-like properties for their immune phenotypes
i.e. MHC expression, cytokine secretion and T-cell killing sensitivity. Experimentally
induced epithelial to mesenchymal transition in a syngeneic mouse model of melanoma
would also be a powerful tool to measure the contribution of this phenotype to immune
evasion. Proliferation, migration and other metabolic features could also be tested which
could test potential non-immune specific mechanisms of better outcomes.
In Vitro MicroRNA Gain of Function Screening
Lentiviral gain of function screens are powerful genetic screening tools that allow us to
identify genes that regulate specific phenotypes. Before the laboratory shutdown and
restrictions on on-campus movement between research buildings we were part-way
through a gain of function pooled microRNA screen testing the effect of each human
microRNA on the sensitivity of melanoma cell lines to T-cell killing. The aim of this
experiment was to use an unbiased screening approach to identify microRNAs that can
mediate melanoma sensitivity to T-cell killing. We planned to identify candidate
microRNAs by transfecting melanoma cell lines with a pooled-gain-of-function-lentivirallibrary covering all annotated human microRNAs and measuring enrichment and depletion
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of specific microRNAs after a T-cell killing assay described above. We would then identify
the mechanism of immune-associated microRNA activity in melanoma by identification of
differentially expressed proteins by RPPA in microRNA-transfected cell lines vs control.
We can then test if the candidate microRNA directly or indirectly targets the mRNA of that
protein and if targeting that protein using an independent method reproduces the immune
phenotype induced by exogenous expression of the microRNA of interest.
Completion of these experiments will identify microRNAs that could regulate melanoma
immunity and resistance to immunotherapy, providing important new therapeutic targets.
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CHAPTER SIX
MATERIALS AND METHODS

TCGA Melanoma (SKCM) Dataset:
Normalized mRNA (FPKM) and microRNA (RPM) counts from 368 metastatic melanoma
tumors were downloaded from http://gdac.broadinstitute.org/. We applied a purity filter
removing samples with <80% tumor nuclei leaving 322 samples for further analysis.
Melanoma Cell Line dataset:
Normalized mRNA (FPKM) and microRNA (RPM) counts were generated from a cohort
of metastatic melanoma patients at The University of Texas MD Anderson Cancer Center
as previously described [189, 190]. Genomic data are available from the European
Genome-Phenome Archive (EGA) under accession EGAS00001004536 upon valid request
to the applicable Data Access Committee as indicated via the EGA.
Pre-PD-1 Treated Cohort of Melanoma Patients
Twenty-nine patients with AJCCv8 stage III or IV melanoma undergoing PD-1 immune
checkpoint blockade at the University of Texas MD Anderson Cancer Center were
included in this study (Table 1). All patients had cutaneous-type or unknown primary
melanoma. \ Twenty (67%) patients were male, nine (31%) patients were female.
Seventeen (59%) patients had prior ipilimumab treatment. Pre-treatment biopsies were
consented and collected under institutional-review-board-approved no more than 6 months
prior to commencement of pembrolizumab or nivolumab therapy and with no intervening
therapy. Best Overall Response (BOR) was calculated using RECIST 1.1 criteria Fourteen
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(48%) patients were classified as receiving clinical benefit (BOR; stable disease >6months,
complete or partial response), while Fifteen (52%) patients were classified as not receiving
clinical benefit (BOR; progressive disease). Survival statistics were calculated from the
start date of PD-1 inhibitor treatment. Median Progression-Free Survival (PFS) in the nonclinical benefit group was 83 days (range; 20-NA), median PFS was not reached in the
responder group (range; 257-NA). Lesion specific responses were available for thirteen
(45%) patients where incisional biopsies were performed.
mRNA & MicroRNA Expression Analysis in clinical samples: Total RNA was extracted
from snap-frozen macrodissected melanoma tumors using the AllPrep DNA/RNA/miRNA
Universal Kit (Qiagen) and quality assessed using the Agilent 2100 Bioanalyzer. 40-80ng
of total RNA was used as input for library preparation with the Illumina TruSeq RNA
Access library prep kit following the manufacturer’s instructions. 12-plex sequencing
pools were sequenced using one high-output run of 76bp paired-end reads on an Illumina
NextSeq 500 system at the University of Texas MD Anderson Cancer Center Sequencing
and Microarray Facility (SMF). Fastq files underwent quality control using FastQC
(v0.11.5) and removal of reads containing 15 contiguous low-quality bases (phred score
<20) prior to STAR 2-pass alignment (v2.5.2b) to Gencode v19 with default parameters
followed by post-alignment quality assessment using RNASeQC (v1.1.8). After samplelevel merging of BAM files removing one pool having poor Spearman correlation to a
duplicate pool from the same sample, reads were quantified using htseq-count (v0.6.1) and
normalized into fragments per kilobase of transcript per million mapped reads (FPKM).
For microRNA sequencing, total RNA samples was used as input for small RNA
sequencing library preparation using the unique molecular identifier enabled QIAseq
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miRNA Library Kit (Qiagen). Samples were sequenced using 76bp single end reads on an
Illumina NextSeq 500 and raw UMI count data generated using the QIAseq miRNA
analysis pipeline available at geneglobe.qiagen.com. Secondary analysis was performed in
R using the DESeq2 package for differential expression analysis and count normalisation
using the variance stabilizing transformation (vst) method.
MCP Counter
We used MCP counter to estimate relative and absolute abundance of the component cell
types of the tumour microenvironment, including various immune and stromal cell
populations from RNA sequencing data. We used the ‘MCPCounter’ R package
(https://github.com/ebecht/MCPcounter) as previously described [161].
Cox Proportional Hazard Model
Samples were stratified either into two groups, either above or below the median
expression of the predictor variable, or into tertiles. The survival variable of each group,
either time to a progression event (Progression free survival analysis) or a death event
(Overall survival analysis), was then tested using Cox’s proportional hazard model using
the
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package
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Confidence Intervals. R functions were used with default settings as described in the user
guide.
Kaplan Meier Curves
Samples were stratified into two or three groups based on expression of the predictor
variable as described for the cox-proportional hazard model. Kaplan Meier curves and log129

rank p-values comparing overall survival or progression free survival for each variable
were generated using the R functions ‘survfit’ and ‘ggsurvplot’ from the R package
‘Survminer’ (https://cran.r-project.org/web/packages/survminer/index.html) R functions
were used with default settings as described in the user guide.
Correlation Analysis
Correlation analysis of microRNA expression with other molecular features of melanoma
samples was performed using Spearman correlation analysis using the R function ‘rcorr()’
in the ‘Hmisc’ package (https://cran.r-project.org/web/packages/Hmisc/index.html).
Bipartite Network Analysis
Input data for bipartite network analysis was Spearman’s correlation coefficients from
global correlation analysis of microRNA and mRNA expression, as described above, in
TCGA melanoma samples and separately in the melanoma cell line cohort. Correlation
data was formatted in three column dataframes for bipartite network analysis, with column
1 containing the microRNA name, column 2 containing the mRNA name and column 3
containing the correlation coefficient for each pair. MicroRNA-mRNA correlations were
filtered to exclude all microRNA-mRNA pairs that did not show strong negative
associations indicative of microRNA suppression of gene expression (Spearman’s rho <0.4, <-0.6 in TCGA and cell lines respectively). Igraph network objects were created from
dataframes

containing

‘graph_from_data_frame’

filtered
in

correlation
the

data

‘igraph’

using
package

the

R

function

(https://cran.r-

project.org/web/packages/igraph/index.html). Igraph objects were assigned bipartite
mapping using the R function ‘bipartite_mapping’ in the ‘igraph’ package. The network
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statistic ‘degree centrality’ was then called for each microRNA in the igraph object which
was then used to filter the microRNAs with the fewest mRNA associations (<15, <100 in
TCGA and cell line datasets respectively). Incidence matrices of all remaining
microRNA:mRNA correlations were generated using the R function ‘as_incidence_matrix’
in the ‘igraph’ R package. Bipartite networks were then projected from the igraph objects
using the R function ‘visIgraph’ with the ‘layout_nicely’ layout from the ‘visNetwork’
package (https://cran.r-project.org/web/packages/visNetwork/index.html).
Unipartite Network Analysis
Unipartite (one-mode network) igraph objects were generated from the igraph objects from
bipartite network analysis described above using the R function ‘bipartite.projection’ from
the ‘igraph’ package. Adjacency matrices for each dataset were generated using the R
function ‘as_adjacency_matrix’ from the ‘igraph’ package. The following network
statistics were calculated for each microRNA; Degree centrality, betweenness centrality,
closeness centrality and eigen centrality. Unipartite networks were generated using the base
R function ‘plot’ with the igraph layout ‘graphopt’. The thickness of edges between
microRNA vertices were based on the edge weight.
Gene Set Enrichment Analysis
GSEA was performed through the Broad Institutes Molecular Signature Database website
(https://www.gsea-msigdb.org/gsea/msigdb/annotate.jsp).

Gene

set

overlaps

were

compared with the ‘H: Hallmark gene sets’. The top 10 gene sets with an FDR q-value
<0.05 are reported.
Predicted and Validated MicroRNA Target Databases
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The database of experimentally validated microRNA targets, miRTarBase v8, was
downloaded (http://mirtarbase.cuhk.edu.cn/php/download.php). MicroRNA targets were
filtered based on the strongest evidence of regulation (Reporter assays, Western blot and
qPCR)
A database of predicted microRNA targets, TargetScan v7.2, was also downloaded
(http://www.targetscan.org/cgi-bin/targetscan/data_download.vert72.cgi).
Cell Culture
For microRNA studies, human melanoma cell lines, from the adoptive T-cell therapy
program described above, were cultured in complete media at 37ºC and 5% CO2 for a
maximum of 5 passages before experiments were performed. Cell lines were maintained
in the logarithmic growth phase and were passaged when they reached 70-80% confluence
at ratios optimised for each cell line used. For each passage, cells were washed x2 with ice
cold PBS before incubation with 0.25% trypsin [GIBCO] until cells detached. Trypsin was
immediately neutralized using complete media. Cells were then spun @180RCF for 5
minutes to pellet. Media was aspirated before cells were resuspended in 1ml ice cold PBS
to wash. A 10ul aliquot was taken at this stage for cell counting by haemocytometer or
cellometer using manufacturer’s instructions. The washed cells were spun again at 180RCF
for 5 minutes to pellet and PBS aspirated. Cells were then resuspended in complete media
at 1*10^6 cells per ml for downstream applications. Cell lines were STR fingerprinted and
regularly confirmed as mycoplasma negative as described above.
Transient MicroRNA Transfections
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For Transient microRNA transfections cells were seeded in complete media at normal
densities to maintain logarithmic growth in either 96 well, 12 well, 6 well or t25 flasks
depending on the number of cells required per experiment. After 8 hours of culture for firm
attachment to take place, complete media was aspirated and cells were gently washed in
ice cold PBS x2.
Transient transfections were achieved by culturing target melanoma cell lines with the
desired miRIDIAN microRNA mimics or inhibitors (Dharmacon) at a concentration of
10nm in serum-free OptiMEM media for 16 hours. We used a cationic lipid transfection
reagent, Dharmafect (Dharmacon), at a concentration of 2µl/ml according to
manufacturer’s instructions to facilitate transfection. Concentration of transfection reagent
was optimized per cell line by measuring transfection efficiency of a fluorescently labelled
microRNA mimic control (Dharmacon) by fluorescent microscopy). After transfection,
transfection media was aspirated and cells washed 1x with ice cold PBS before cells were
returned to standard culture conditions for 72hrs for microRNA phenotypes to manifest
before downstream applications.
RNA Extractions, cDNA & Mature microRNA preparations.
RNA Extractions from cell lines for downstream applications was performed using Norgen
Total RNA Purification Kit (Norgen Biotek) using manufacturer’s instructions. In short,
cell lines were harvested from 6-well plate cultures at 80% confluency (0.5-1 x 106 cells).
Culture media was then aspirated and cells were gently washed twice with ice cold PBS.
PBS was aspirated and 350µl lysis buffer was added to each well of the plate for 5 minutes
with gentle agitation. Lysate was transferred to a microfuge tube and mixed with 200µl
100% ethanol and samples were vortexed for 10 seconds. All lysate was then bound to
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columns and centrifuged at 3500 RCF for 1 minute and flow through discarded. Columns
were then washed x3 with 400µl and spun at 3500 RCF for 1 minute. Column was then
dried by spinning for 2 minutes at 14,000 RCF. RNA was then eluted from the column
using elution buffer supplied with the kit. 50µl elution buffer was added to each column
and then spun for 2 minutes at 200 RCF and then 1 minute at 14,000 RCF. RNA quantity
and quality was then assessed using Nano Drop One (ThermoFisher Scientific), using
Norgen Biotek elution buffer as blank calibration samples. RNA samples with 260/280
ratios <1.9 were rejected and extraction repeated. Samples were stored at -20ºC for shortterm storage (<1 week) prior to downstream applications or stored for up to 12 months at
-80ºC if required.
cDNA was generated from total RNA using High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) using the manufacturer’s instructions. In brief, 500ng total RNA
was added to cDNA master mix including reverse-transcription buffer, dNTP mix, reversetranscription random primers, MultiScribe reverse transcriptase and RNase inhibitor
supplied with kit at recommended concentrations. Thermal cycling conditions were as
follows: Step 1 at 25ºC for 10 minutes, step 2 at 37ºC for 120 minutes, step 3 at 85ºC for 5
minutes before sample returned to 4ºC for downstream use or freeze at -20ºC or -80ºC for
short or long term storage respectively.
Mature microRNA cDNA was generated from total RNA using Taqman Advanced miRNA
cDNA Synthesis Kit (ThermoFisher Scientific) and using manufacturers instructions. In
brief, 10ng of total RNA was used per reaction. RNA was polyadenylated using polyA
buffer, PolyA enzyme and ATP supplied with kit at recommended concentrations for 45
minutes at 37ºC before the reaction was stopped at 65ºC for 10 minutes and then returned
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to 4ºC before ligation. The ligation was performed using RNA ligase, ligation adaptor,
ligase buffer and PEG 8000 supplied with kit at recommended concentrations for 60
minutes at 16ºC and then returned to 4ºC before reverse transcription. Reverse transcription
was performed using universal reverse transcription primer, reverse transcription enzyme,
dNTP mix and reverse transcription buffer provided with the kit at recommended
concentrations at 42ºC for 15 minutes before the reaction was stopped at 85ºC for 5 minutes
and then returned to 4ºC before the miR-amplification reaction. The miR-amplification
reaction was then performed using miR-amplification master mix and primer mix supplied
with the kit at the recommended concentrations using the following cycling conditions:
Enzyme activation at 95ºC for 5 minutes x1, denature at 95ºC for 3 seconds and
anneal/extension at 60ºC for 30 seconds x14, stop reaction at 99ºC for 10 minutes, then
return sample to 4ºC for downstream use or freeze at -20ºC or -80ºC for short or long term
storage respectively.
All reactions were performed using a Mastercycler Nexus thermocycler (Eppendorf)
qPCR
qPCR reactions were performed in MicroAmp EnduraPlate Optical 96-Well Fast Celar
Reaction plates (Applied Biosystems) on QuantStudio Flex analyser (Applied Biosystems).
Data was analysed using QuantStudio 6 & 7 Flex Real Time PCR System Software v1.0
(Applied Biosystems).
MicroRNA PCR reactions were performed using 5 µl of 1:10 diluted template from
advanced microRNA synthesis reaction described above. Assays were repeated with
undiluted template if sample was below detection threshold. 1 µl Taqman advanced
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miRNA assay (Applied Biosystems) corresponding to the desired target microRNA, 10 µl
Taqman Fast Advanced Master Mix x2 (Applied Biosystems) and 4 µl PCR-grade water
were added to each template for a 20 µl reaction. Thermal cycling conditions were set as
follows:
Enzyme activation – 20 seconds @ 95 ºC x1.
Denature – 1 second @ 95 ºC, Anneal/Extend 20 seconds @ 60 ºC x40.
Number of target copies per reference gene was calculated by comparing CT values from
duplicate reactions of target microRNAs compared to CT values from duplicate reactions
of stably expressed microRNAs – miR-103a-3p, 423-3p, 26a-5p. Comparisons were made
independently for each cell line used in the experiment.
For qPCR of cDNA synthesized from total RNA we used SYBR green reactions per
manufacturer’s instructions. Briefly, 0.3 µl of each forward and reverse primer (Sigma) for
each target were added to 3.75 µl SensiMix SYBR No-Rox (meridian Bioscience) and 1.15
µl PCR-grade H2O. 2.5 µl of 1:10 diluted template from cDNA reaction described above
was added to each reaction for a total volume of 8 µl. Thermal cycling conditions were as
follows:
Denature template – 1 minute @ 94 ºC, anneal primers – 2 minutes @ 55 ºC, Extension –
3 minutes @ 72 ºC x40.
The number of target copies per reference gene was calculated as described above but using
GAPDH as the reference gene.
Legendplex Cytokine Panel
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To measure cytokine secretion from melanoma cell lines we quantified expression of a
customized panel of melanoma and immune specific cytokines using a custom,
multiplexed, flow cytrometry, bead-based, immuno-assay, LEGENDplex (Biolegend). The
custom panel contained the following target cytokines: IL-1a, IL-1b, IL-2, IL-6, CCL2
(MCP1), IL-10, TNF-a, TNF-b, IFN-g and VEGF. All assays were performed according to
manufacturer’s instructions. In brief, cell lines were cultured until 70% confluent in normal
culture conditions. Growth medium was replaced 24 hours before assay with fresh media
with additional 10nM TNFa to stimulate cytokine secretion. Cell culture media was
collected and centrifuged to remove cell debris and was assayed immediately without
dilution. For cell lines that had undergone transient microRNA transfections (described
above), cell culture supernatant was assayed 96hrs after transfection in the same manner
i.e. fresh media was applied for the purpose of cytokine collection 72 hours posttransfection.
Standard curves for each analyte were generated by serially diluting each standard
(supplied with kit) 1:4 with assay buffer (supplied with kit) six times to generate a 7 point
dilution from undiluted to 1:4096 dilution and a blank standard consisting of only assay
buffer.
Samples were assayed in duplicate on a 96-well v-bottomed plate. 25µl of standard or cell
culture supernatant was added to 25µl assay buffer. Mixed assay beads were vortexed
before adding 25µl to each sample and incubated for 2hrs with moderate shaking at room
temperature protected from light. Plates were centrifuged at 250 RCF for 5 minutes to pellet
beads. Supernatant was discarded and plate was washed with 200µl of wash buffer per well
before pelleting beads and discarding wash buffer. 25µl of detection antibodies were then
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added to each well before incubating for 1 hour at room temperature while shaking at
800rpm protected from light. 25µl of SA-PE was then added directly to each well and plate
was returned to the plate shaker for an additional 30 minutes. Beads were then pelleted and
washed as above before each sample was resuspended in 150µl of wash buffer ready for
FACS acquisition.
For data collection plates were loaded onto a BD Accuri C6 cytometer (BD Biosciences).
Samples were gated on size to count only LEGENDplex beads A&B. 20,000 beads per
sample were acquired and data saved as FCS files. FCS files were analysed using
LEGENDplex data analysis software which quantified cytokine levels per sample by
comparing mean fluorescence intensity values from each bead population against standard
curves from known cytokine concentrations.
HLA & PDL1 Flow Cytometry
To quantify surface HLA-ABC and PD-L1 expression on melanoma cell lines we harvested
cells at 70% confluence by trypsinisation then washed in ice cold PBS twice. One million
cells were resuspended in 1ml ice cold FACS buffer (PBS, 10% FBS, 1% sodium azide).
50µl of each sample (5*104 cells) was added to a round bottom 96-well plate in duplicate
for staining. Samples were stained using directly conjugated anti PD-L1 (APC anti-human
CD274/ B7-H1/ PD-L1, clone:29E.2A3, Biolegend) or anti HLA-ABC (HLA-ABC
Monoclonal Antibody, W6/32, FITC, eBioscience) antibodies at a concentration of 1:100
in 50µl FACS buffer for 1 hour at room temperature in the dark. Samples were centrifuged
at 400 RCF for 5 minutes and washed with 100µl FACS buffer twice. Live/Dead staining
for cell viability was achieved by adding 5µl of propidium iodide (PI) staining solution
(10µg/ml in PBS) to each sample immediately prior to acquisition.
138

Sample acquisition was performed using a BD Accuri C6 cytometer (BD Biosciences) and
samples were gated based on cell size and negative PI staining. Mean Fluorescence
intensity for PD-L1 and HLA was measured from 10,000 live cells.
T-Cell Co-Culture Experiments and Chromium Release Assay
Melanoma sensitivity to T-cell killing was quantified using a chromium (Cr-51) release
assay performed on melanoma cells that had been co-cultured with MART-1-specific
human cytotoxic T-cells.
MART-1-specific T-cells were generated and prepared for the killing assay as previously
described [191, 192]. Melanoma cell lines were tested for MART-1 expression by flow
cytometry and HLA matched prior to assay. Melanoma negative controls included MART1 + / HLA mismatched cells, MART-1 - / HLA matched cells, MART-1 - / HLA
mismatched cells cell line. For co-culture assay, melanoma cell lines were cultured until
70-80% confluency under normal cell culture conditions. Cell lines that had undergone
transient microRNA transfections (as described above) were harvested 72hrs posttransfection. Cells were detached by trypsinisation, washed, counted and resuspended at
2*106 cells/ml in complete media. For Cr-51 pulsing, enough cells for 2000 per co-culture
condition were transferred to a 15 ml conical and diluted to the nearest whole ml with
complete media. In a radioactive material designated lab, 100µl of 0.1 mCi Cr-51 was
added per ml of cells and incubated for 1 hour. Cells were thoroughly washed by
centrifugation and resuspension in fresh complete media twice before resuspending cells
at a concentration of 2*104 cells per ml in complete media. 100 µl of this cell suspension
was then added to the appropriate wells of a u-bottomed 96-well plate for co-culture. 100
µl of T-cells were then added to each well at concentrations to achieve effector to target
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(E:T) ratios between 5:1 to 20:1 as optimized per cell line. Negative controls consisted of
wells containing only target cells with no effector cells to measure baseline Cr-51 release.
Positive controls consisted of wells containing target cells and trypan lysis buffer to
measure complete Cr-51 release. After a 4 hour incubation 30µl of supernatant from each
condition was transferred to a LumaPlate-96 (PerkinElmer) and allowed to dry overnight.
The LumaPlates were read the following day and Cr-51 release was calculated as a
percentage of total Cr-51 (positive control) minus baseline Cr-51(negative control) release.
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